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Abstract 
Chronic Obstructive Pulmonary Disease (COPD) is an incurable disease characterized by 
ongoing processes of inflammation and repair of the pulmonary epithelium. The 
dysregulation of the underlying processes that govern these mechanisms, such as 
epithelial-to-mesenchymal transition (EMT), leads to disease progression. In-silico 
analysis of the regulation of expression of FAM13A, a COPD-susceptibility gene 
identified in multiple genetic association studies, identifies a putative COPD-associated 
enhancer. In vitro analysis of this putative enhancer reveals a possible inhibitory function 
in lung adenocarcinoma cells in response to time-dependent IFN-γ treatment. 
Additionally, IFN-γ is shown to regulate FAM13A in normal lung epithelial cells with a 
loss of this regulation in lung adenocarcinoma cells at both the transcriptional and 
translational level. This study allows a better understanding of the regulation of FAM13A 
in the context of COPD and provides insight into the link between COPD and lung cancer. 
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1. Introduction 
1.1. Chronic Obstructive Pulmonary Disease 
Chronic Obstructive Pulmonary Disease (COPD) is defined as chronic inflammation of 
the lung resulting in the progressive and irreversible obstruction of airflow into and out 
of the lungs (Berndt et al., 2012; Decramer et al., 2012). It is attracting increasing 
attention as it affects around 64 million people around the world, and is currently the 
fourth leading cause of death globally (World Health Organization), resulting in 
substantial morbidity and mortality. Because COPD is a progressive disease with limited 
treatment options that only slow the loss of lung function rather than cure it (Decramer et 
al., 2012), it is expected to become the third leading cause of death in the world between 
2020 and 2030 (Murray and Lopez, 1997). As such, it is one of the major chronic diseases 
facing society (Murray and Lopez, 1997) and consequently imposes an enormous 
financial and clinical burden on individuals and communities (Halpin and Miravitlles, 
2006). 
1.2. COPD at the cellular level 
Although COPD is classified as a heterogeneous disease as seen by the variability of 
clinical phenotypes (Barrecheguren and Miravitlles, 2016), two main pathological 
processes have been identified (Hogg et al., 2004): emphysema which is caused by the 
destruction of the lung parenchyma and alveolar space (McDonough et al., 2011), and 
fibrosis and tissue remodelling that leads to the narrowing of the small airways (Barnes, 
2016; Crystal, 2014; Nussbaumer-Ochsner and Rabe, 2011; Perotin et al., 2014). At the 
cellular level, COPD affects the different cells that make up the large airways, small 
airways (or bronchioles), the alveolar space, the lung parenchyma and the pulmonary 
vessels (Barnes, 2000, 2004; Fabbri et al., 2003; Miglino et al., 2012b; Pesci et al., 1998; 
Saetta et al., 2001). In the large airways, and proportional to cough and mucus production 
(characteristic of chronic bronchitis), mucous gland enlargement and goblet cell 
hyperplasia have been observed. In the small airways, goblet cell metaplasia, a decrease 
in the number of surfactant-secreting Clara cells, an increase in the number of mucous-
secreting cells, and an increase in the infiltration of mono-nuclear inflammatory cells are 
characteristic changes (Barnes, 2000; Shapiro and Ingenito, 2005). As a result of 
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increased proliferation of basal airway epithelial cells, the airway epithelium of patients 
with chronic bronchitis and COPD often shows squamous metaplasia (Barnes, 2016). 
This may be accompanied by smooth muscle hypertrophy and fibrosis of the airways. In 
the alveolar space, changes include chronic inflammation and mechanical destruction of 
the alveolar walls (Figure 1.1) (Shapiro and Ingenito, 2005). Such damage to fibres of the 
alveolar walls concentrates stress in the remaining adjacent fibres because the lung is 
under constant positive trans-pulmonary pressure. As a result, fibres can rupture, leading 
to progression of disease through direct mechanical injury and structural remodelling. 
Collectively, these changes result in airway narrowing due to edema, excess mucus 
secretion and cellular infiltration, and consequently create a predisposition for 
nonspecific inflammatory hyper-reactivity (Shapiro and Ingenito, 2005). 
 
Figure 1.1: Computer simulation of lung section at the alveolar level portraying the 
progression of emphysema. Persistent inflammation in response to environmental irritants 
and mechanical breakage of alveolar walls results in damage to fibres. Because the lung is 
under constant trans pulmonary pressure, the damage to fibres concentrates stress in the 
remaining adjacent fibres. Ongoing inflammation disrupts wound healing leading to 
progression of disease through direct mechanical injury and structural remodelling. 
Adapted from (Shapiro and Ingenito, 2005). 
1.3. COPD at the molecular level 
The severe damage to the airway epithelium in individuals with COPD is initiated by 
environmental stimuli that affect a range of lung cells including immune cells and airway 
epithelial cells. The role of epithelial cells in the defence of the airways such as goblet 
cell mucus production and secretion of antioxidants, anti-proteases and 
defensins/cathelicidins, is impaired and consequently increases susceptibility to infection 
(Barnes, 2016). Environmental risk factors for the development of COPD include the 
prolonged exposure to biomass fuels such as coal, straw and wood (Global Initiative for 
Chronic Obstructive Lung Disease (GOLD), 2017), occupational exposure to organic and 
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inorganic dusts, and to chemical vapours and fumes (Balmes et al., 2003; Global Initiative 
for Chronic Obstructive Lung Disease (GOLD), 2017). However, the major risk factor 
for COPD development remains the prolonged exposure to tobacco smoke (Global 
Initiative for Chronic Obstructive Lung Disease (GOLD), 2017; Pauwels et al., 2001). 
Although the adverse effects of smoking on human health are well established (Didon et 
al., 2011; Kim et al., 2008; Patel et al., 2008), there is still much to understand regarding 
the processes that contribute to smoking-related diseases. 
Smoking induces airway dysfunction and injury through complex mechanisms involving 
apoptosis, oxidative stress and inflammatory responses to smoking (Barnes et al., 2003; 
Didon et al., 2011; Holt and Schon-Hegrad, 1987; Sopori, 2002). Between 30 to 50% of 
smokers develop COPD (Salvi and Barnes, 2009), although with different rates of 
pulmonary function reduction between smokers with similar smoking exposures.  At the 
molecular level, cigarette smoke not only inhibits the proliferation of normal lung 
fibroblasts (Nakamura et al., 1995), but also induces cellular senescence (Nyunoya et al., 
2006) and inhibits alveolar repair (Miglino et al., 2012a; Rennard et al., 2006). Acute 
cigarette smoke exposure increases air space epithelial permeability in human, animal 
and in vitro studies in as little time as one hour (Morrison et al., 1999; van der Vaart et 
al., 2004). 
Additionally, cigarette smoke exposure increases local inflammation, indicated by an 
increase in the number of inflammatory cells in the lung (van der Vaart et al., 2004). 
Smoking is associated with the infiltration of the lungs by neutrophils, macrophages, T 
lymphocytes (predominantly TC1, TH1, and TH17 cells), innate lymphoid cells (natural 
killer cells, eosinophils, mast cells, dendritic cells) and B lymphocytes (Barnes, 2008, 
2016; Brusselle et al., 2011; Hogg et al., 2004).  These cells release pro-inflammatory 
mediators into the lungs (Barnes et al., 2003; van der Vaart et al., 2005) such that the 
intensity of infiltration by activated immune cells correlates with the degree of 
progression of COPD (Domagala-Kulawik et al., 2003; Gadgil et al., 2006; Hogg et al., 
2004; Tetley, 2005). In fact, studies show strong correlation between the density of T 
lymphocytes in the lungs and the extent of emphysema in COPD lungs (Churg et al., 
2008; Finkelstein et al., 1995; Grumelli et al., 2004; Saetta et al., 1998). Furthermore, it 
has been shown that smoke exposure leads to a robust production of T helper 1 (TH1) cell 
pro-inflammatory cytokines (TNF-⍺, IL-12, and IFN-γ) (Kearley et al., 2015). The 
cytokine most characteristic of TH1 responses is IFN-γ (Scott, 1991) which is a key player 
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in the orchestration of the TH1 inflammatory response characteristic of COPD (Brozyna 
et al., 2009; Hodge et al., 2007; Hodge et al., 2012; Majori et al., 1999; Zheng et al., 
2005). In fact, lung lymphocytes of COPD patients with loss of lung function secrete 
more IFN-γ compared to lymphocytes of healthy individuals (Grumelli et al., 2004). In 
addition to TH1 cells (Mosmann and Coffman, 1989), IFN-γ is also produced by other 
activated inflammatory cells, including natural killer cells (Gough et al., 2008; Perussia, 
1991; Schroder et al., 2004), activated CD8+ cytotoxic (TC1) cells (Sad et al., 1995), B 
cells and professional APCs (Schroder et al., 2004). 
IFN-γ is involved in the regulation of several different aspects of the immune response 
and includes: stimulation of bactericidal activity of phagocytes, stimulation of antigen 
presentation through class I and class II major histocompatibility complex (MHC) 
molecules, orchestration of leukocyte-endothelium interactions, effects on cell 
proliferation and apoptosis, and cell cycle control (Gough et al., 2008). It is also able to 
increase epithelial permeability (Adams et al., 1993; Madara and Stafford, 1989) and 
promotes the activation of the epithelium through a variety of mechanisms including the 
induction of the enzyme indoleamine dioxygenase (IDO) (Shirey et al., 2006), and the 
expression of toll-like receptors (Armstrong et al., 2004). 
It has also been demonstrated that IFN-γ up-regulates the transcription of genes related 
to antigen presentation (MHC class I and II, β2- microglobulin, TAP), TH1 phenotype 
development (STAT-1, T-bet), chemokine-based recruitment of monocytes, T cells, 
eosinophils and basophils (MCP-1, MCP- 2, MCP-3, RANTES), cellular adhesion (VLA-
4, ICAM-1, VCAM-1 molecules), immunoglobulin heavy chain class switch (IFN-γ 
upregulates IgG and downregulates IgE), cytokines network (IL-12, IFN-γ, CD40), 
apoptosis (CD95, caspases), lymphocyte activation (B7-1 and B7-2 molecules), induction 
of the expression of inducible nitric oxide synthase (iNOS) in macrophages (Mills et al., 
2000; Munder et al., 1998; Park and Barbul, 2004) and others (Boehm et al., 1997; 
Teixeira et al., 2005). 
Therefore, IFN-𝛾 plays a key role in macrophage activation, inflammation, host defence 
against intracellular pathogens, tumour surveillance and immuno-editing. In parallel, 
IFN-𝛾 exerts regulatory functions to limit tissue damage associated with inflammation 
and to modulate TH and regulatory T (Treg) cell differentiation through mechanisms 
including attenuation of gene expression, inhibition of migration and differentiation of 
tissue-destructive cells, and inhibition of signalling by tissue-destructive factors (Hu and 
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Ivashkiv, 2009) such as matrix metalloproteinases (MMPs), coagulation factors, 
complement components and enzymes (Barrios-Rodiles and Chadee, 1998; Ho et al., 
2008; Ma et al., 2001; Sanceau et al., 2002; Zhou et al., 2003). Therefore, IFN-𝛾 can 
either augment or suppress inflammation and the associated pathology in a context- and 
disease-specific manner (Hu and Ivashkiv, 2009). 
This pleiotropic characteristic of IFN-𝛾 is the result of complex patterns of cell-specific 
gene regulation (Boehm et al., 1997). Based on its pleiotropic effect and its orchestration 
of seemingly opposing cellular events, IFN-𝛾 may play a dual role in the progression of 
COPD, having both a beneficial and detrimental effect on the epithelial barrier. This is 
accomplished through IFN-γ-induced gene transcription (Figure 1.2). Of the different 
subsets of genes induced by IFN-γ, transcription-regulating genes and transcription 
factors form a major category (de Veer et al., 2001). These include members of the IFN 
response factor (IRF) family of proteins, a family of secondary effectors that mediate 
immune modulation, IFN production following viral infection, and IFN signalling (Au et 
al., 1995; de Veer et al., 2001; Elser et al., 2002). Other transcription factors also induced 
by IFN-γ include signal transducer and activator of transcription 1 (STAT-1) (Krause et 
al., 2006), a central mediator of inflammatory responses (Regis et al., 2008) such that 
humans expressing STAT-1 mutants exhibit increased susceptibility to viral and bacterial 
infections (Chapgier et al., 2006), and T-box21 (TBX21), a TH1 cell-specific transcription 
factor that directs TH1 linage commitment (Lighvani et al., 2001). 
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Figure 1.2: Protein-protein interaction network of IFN-γ constructed by STRING. 
Interactions with a high confidence (>0.7) are visualized. Proteins are clustered using the 
MCL algorithm (Szklarczyk et al., 2015). 
Dysregulation of IFN-γ is implicated in a large number of diseases that are described as 
TH1/TC1 responses (Zheng et al., 2005) such as atherosclerosis (Tellides et al., 2000), 
Crohn’s disease (Bouma and Strober, 2003), rheumatoid arthritis (Vervoordeldonk and 
Tak, 2002), periodontitis (Garlet et al., 2003), Behcet’s disease (Ben Ahmed et al., 2004), 
aphthous ulcers (Borra et al., 2004), autoimmune gastritis (Katakai et al., 2003), and 
uveoritinitis (Foxman et al., 2002). These diseases progress through inflammation and 
remodelling characterized by tissue atrophy and/or destruction (Ben Ahmed et al., 2004; 
Borra et al., 2004; Ehlers et al., 2001; Foxman et al., 2002; Garlet et al., 2003; Katakai et 
al., 2003; Vervoordeldonk and Tak, 2002). In the context of COPD, IFN-γ activates 
endothelial cells (Pober et al., 1986) and epithelial cells (Look et al., 1992) in the lung 
parenchyma inducing adhesion molecule expression, and consequently, supporting the 
recruitment and activation of additional inflammatory cells and circulating leukocytes 
(Cornwell et al., 2010). IFN-γ also causes DNA injury and apoptosis in a variety of cells, 
including airway and type II alveolar epithelial cells in the murine lung resulting in 
alveolar remodelling and emphysema (Wang et al., 2000; Zheng et al., 2005). In animal 
model studies of COPD, over-expression of IFN-γ in murine lung results in a human 
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COPD-like phenotype with progressive emphysema, increased lung volumes, and 
inflammation (Wang et al., 2000). Expression of iNOS is also increased by IFN-γ 
(Robbins et al., 1994), and NO can interact with superoxide leading to peroxynitrite 
generation and nitrotyrosine formation (Ischiropoulos et al., 1992), which may result in 
epithelial damage that is further increased by cigarette smoke-induced oxidative stress 
(Jiang et al., 2016; van der Vaart et al., 2004). This up regulation of the inflammatory 
environment and subsequent increase in the intensity of the inflammatory response 
ultimately leads to tissue destruction of the lungs and emphysema (Finkelstein et al., 
1995; Janoff, 1983; Retamales et al., 2001; Saetta et al., 2001; Shapiro, 1994). 
Additionally, IFN-γ activates an apoptosis-dependent positive feedback loop that drives 
and amplifies the chronic nature of the inflammatory response. This positive feedback 
loop may be responsible for the progressive lung function decline and chronic 
inflammation (Figure 1.3) that are seen in COPD (Zheng et al., 2005).  
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Figure 1.3: The chronic cycle of COPD. Continuous exposure to environmental irritants such 
as cigarette smoke elicits a TH1 inflammatory response characterized by the production of 
IFN-γ. Dysregulated IFN-γ induces airway epithelial injury through various mechanisms 
including apoptosis. This, and in conjunction with defective epithelial repair in genetically 
susceptible individuals results in impaired lung defence and subsequent microbial and viral 
infiltration, further promoting the induction of an aggressive inflammatory response in 
COPD. 
1.4. Wound Healing and EMT 
In COPD, chronic inflammation and structural remodelling have a cause/effect 
relationship (Finkelstein et al., 1995; Jeffery, 2000; Saetta, 1999; Senior, 2000; Wang et 
al., 2000) such that chronic inflammation causes injury and apoptosis which in turn leads 
to structural remodelling through dysregulated or insufficient wound healing. Lung 
epithelial wound healing, in response to injury induced by cigarette smoke and the chronic 
inflammation-inducing dysregulated IFN-γ in COPD, is a complex and highly dynamic 
process (Gardner et al., 2010; Leoni et al., 2015) consisting of a tightly regulated series 
of cellular and biochemical events that function to restore tissue integrity after injury. 
Immune cells, mainly neutrophils and macrophages, play a crucial role in inflammation 
and host defence, and in the promotion of the wound-healing process through their 
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secretion of cytokines, lymphokines and growth factors (Park and Barbul, 2004; Witte 
and Barbul, 1997). These include oxygen-free radicals and proteases that do not 
differentiate between foreign bodies and viable tissues (Witte and Barbul, 1997), pro-
inflammatory cytokines such as TNF, IL-1, IL-6, and IL-12 (Leoni et al., 2015; Murray 
et al., 2014; Murray and Wynn, 2011) and iNOS (Lee et al., 2001; Reichner et al., 1999; 
Schaffer et al., 1997). 
Cytokines and growth factors released in the inflammatory environment, such IFN-γ 
(Park and Barbul, 2004), TGF-β (Pakyari et al., 2013), and EGF (Steenfos, 1994) allow 
the recruitment of fibroblasts and myo-fibroblasts into the wounded region to initiate the 
proliferative phase by depositing collagen and glycosaminoglycans that compose the 
extracellular matrix (Behm et al., 2012). This then allows for undifferentiated epithelial 
cells to migrate across the wounded region in an effort to reconstruct the disrupted 
structure through a process known as epithelial-to-mesenchymal transition (EMT) 
(Greenhalgh, 1998; Stone et al., 2016).  
20 
 
 
Figure 1.4: Epithelial-to-mesenchymal transition. EMT involves the phenotypic conversion 
from a differentiated and non-motile epithelial cell to a much more motile mesenchymal-
type cell. It is accompanied by the loss of apico-basal polarity and epithelial marker proteins 
and the gain mesenchymal proteins. There is also the loosening of tight junctions, Gap 
junctions, and adherens junctions formed by E-cadherin and β-catenin. Additionally, cells 
undergoing EMT are able to produce interstitial matrix components. 
EMT, which plays an important role in embryonic development, tissue fibrosis, and 
cancer progression, involves the phenotypic conversion from a differentiated and non-
motile epithelial cell to a much more motile mesenchymal-type cell (Bartis et al., 2014). 
However, the EMT in wound healing is not separate from injury, rather, pathology results 
when the normal response to damage is dysregulated (Puchelle et al., 2006). The 
pathological remodelling of the epithelium that occurs during COPD is the tipping of the 
balance between EMT and regeneration of physiologically appropriate proportions of 
basal, secretory and ciliated cells (Rock et al., 2010). This considerably disturbs the 
epithelial barrier function of airway epithelium via dysregulation of inflammatory 
cytokines and mediators such as IFN-γ and results in leakiness of airway surface 
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epithelium corresponding to a low protective barrier against aggressive agents that leave 
the lungs particularly exposed (Puchelle et al., 2006). Repeated injury to the lung 
epithelial barrier through both smoking and IFN-γ-induced apoptosis, oxidative stress and 
inflammation, with impaired or dysregulated repair processes and incomplete restoration 
of the cellular barrier function favours the recurrence of infections in COPD. 
EMT (Figure 1.4) is accompanied by the loss of epithelial marker proteins such as E-
cadherin, zonula occludens-1, and cytokeratin, and the gain mesenchymal proteins such 
as vimentin, ⍺-smooth muscle actin and fibroblast-specific protein-1. Additionally, cells 
undergoing EMT are able to produce interstitial matrix components type I collagen and 
fibronectin (Rastaldi, 2006; Savagner, 2001; Tian et al., 2011). One of the earliest signs 
of EMT is the loosening of adherens junctions (Bartis et al., 2014) that maintain 
intercellular physical contact and epithelial cell polarity (Green et al., 2010; Meng and 
Takeichi, 2009). Adherens junctions, the primary cellular determinant of epithelial barrier 
functions (Tian et al., 2011), consist of a family of cytoplasmic proteins called the 
catenins that bind to cytoskeletal components. The catenins associate with cadherin 
receptors to form cadherin/catenin-based anchoring junctions thus mediating the adhesion 
of neighbouring cells (Meng and Takeichi, 2009) through organizing and tethering 
microfilaments as well as integrating intra- and inter-cellular signalling (Gumbiner, 
2005). One such complex, the E-cadherin/β-catenin protein complex, is active in 
epithelial to mesenchymal (EMT) and mesenchymal to epithelial (MET) transitions (Tian 
et al., 2011). Full cellular adhesion is dependent on the binding of β-catenin to cadherin 
and the consequent bridging of cadherin with ⍺-catenin, the actin-binding protein. As a 
result, β-catenin is an excellent mediator of signal-induced changes in cadherin-based 
adhesive cellular contacts (Niessen, 2007). 
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Figure 1.5: Wnt/β-catenin signalling pathway. Upon the binding of Wnt ligands to the 
Frizzled receptors and LRP5/6, the APC/Axin/GSK3β destruction complex is disrupted and 
β-catenin is stabilized. β-catenin accumulates in the cytoplasm and is free to translocate 
into the nucleus where it acts as a transcriptional coactivator of transcriptional factors of 
the TCF/LEF family. In the absence of Wnt, β-catenin is phosphorylated by GSK3. 
Phosphorylated β-catenin is targeted ubiquitination and subsequent degradation by 
proteasome.  
β-catenin is also a key player in the Wnt/β-catenin signalling pathway (Figure 1.5), and 
an inducer of EMT in human airway epithelia in response to nicotine (Zou et al., 2013). 
β-catenin regulates tracheal epithelial basal cell growth and lineage choice subsequent to 
tracheal damage, such that the inhibition of β-catenin signalling decreases cell 
proliferation and inhibits normal epithelial repair thus decreasing cellular EMT 
phenotypes (Giangreco et al., 2012). In the absence of Wnt signalling, cytosolic β-catenin 
associates with axin and adenomatous polyposis coli, components of a multi-protein 
destruction complex. This association facilitates the phosphorylation of serine residues in 
the N terminus of β-catenin (Tian et al., 2011) and its subsequent recruitment to the 
ubiquitin degradation complex that maintains it at low levels in the cytosol. Upon 
stimulation by Wnt ligands, β-catenin is stabilized and translocates to the nucleus to 
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activate the expression of Wnt target genes through T-cell factor (TCF)/lymphoid 
enhancer factor (LEF) transcription factors and subsequently promotes various cellular 
pathways such as cell proliferation, cellular adhesion, tissue remodelling, tumour 
development and airway epithelial repair in response to injury (Clevers, 2006; Grigoryan 
et al., 2008; Jiang et al., 2016; Tian et al., 2011). Loss of E-cadherin likely promotes β-
catenin release and facilitates EMT, whereas the expression of E-cadherin can reverse the 
transformed phenotype (Auersperg et al., 1999; Cano et al., 2000; Hay and Zuk, 1995; 
Vleminckx et al., 1991). Therefore, the loss of cell-cell adhesion triggers EMT and is 
associated with diseases involving EMT (Tian et al., 2011) such as COPD. 
1.5. Defective Resolution of Inflammation and Repair 
The persistence of inflammation in COPD after discontinuing smoking indicates the 
presence of self-perpetuating pro-inflammatory mechanisms (Gamble et al., 2007). At 
least 25% of COPD patients are non-smokers (Zeng et al., 2012) with significant 
variability in the development of chronic airflow obstruction between cigarette smokers 
(Burrows et al., 1977; Fletcher, 1976; Silverman, 2006). There are higher rates of airflow 
obstruction in first-degree relatives of patients with COPD when compared to control 
subjects, suggesting that genetic susceptibility contributes to the development of COPD 
(Cohen, 1980; Kueppers et al., 1977; McCloskey et al., 2001; Silverman, 2006; Silverman 
et al., 1998). Furthermore, a direct relation between shared genotype and pulmonary 
function has been demonstrated in families and twins not selected for respiratory 
problems indicating that the variation in pulmonary function is influenced by genetic 
factors (Hersh et al., 2011; Lewitter et al., 1984; Redline et al., 1989). Therefore, several 
lines of evidence indicate that COPD development is not the result environmental factors 
only, but rather an interplay between both environmental and genetic risk factors (Berndt 
et al., 2012; Jiang et al., 2016). In this regard, “healthy smokers” who don’t suffer from 
airflow limitation have a similar but attenuated or less aggressive pattern of inflammation 
and mediator expression, whereas COPD patients suffer from an amplified inflammatory 
response that is even further increased during exacerbations in response to bacterial or 
viral infection (Barnes, 2016). This indicates that the loss of a balanced pro-inflammatory 
immune response leads to the development of COPD. In addition to this, there also exists 
dysregulated wound healing of the epithelium in COPD resulting in a compromised 
epithelial barrier (Gardner et al., 2010). Therefore, although the molecular basis for this 
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amplified inflammatory response in COPD is yet to be completely understood, it is 
thought to be at least partly determined by genetic factors (Barnes, 2016) acting on the 
immune system and the lung epithelium. 
The only well-established genetic risk factor for the development of COPD, however, is 
a deficiency of the serine protease ⍺1 anti-trypsin. The deficiency of this enzyme, 
particularly in combination with smoke and other irritants, results in an increased risk of 
pan-lobular emphysema development (Mannino and Buist, 2007; Shapiro and Ingenito, 
2005). However, ⍺1 anti-trypsin deficiency accounts for only 1-3% of COPD cases. This 
indicates the presence of additional genetic risk factors that determine susceptibility to 
COPD development. Several candidate genes and genetic variants linked to COPD 
susceptibility have been identified by Genome Wide Association Studies (GWAS) that 
identify disease-associated polymorphisms (Bosse, 2009; Cho et al., 2010; Cho et al., 
2012; Cho et al., 2014; Pillai et al., 2009). 
1.6. Genome Wide Association Studies 
GWAS provide an unbiased approach to identifying genetic susceptibility loci in common 
complex diseases (Weiss and Silverman, 2011) by identifying associations between 
genetic sequence variants and a range of common genetically complex illnesses such as 
heart disease, lung disease, auto-immune diseases, and psychiatric disorders. GWAS have 
proven to be a valuable tool in identifying novel therapeutic targets by providing a better 
understanding of the biological and cellular pathways of health and disease (McCarthy et 
al., 2008; Visscher et al., 2012). 
Each human genome includes around 4 million single nucleotide polymorphisms (SNPs). 
A GWAS does not genotype all of these SNPs but instead makes use of “tagging SNPs”. 
Tagging SNPs are a collection of SNPs that “tag” individual haplotypes across the human 
genome by making use of linkage disequilibrium. Linkage disequilibrium is defined as 
the non-random tendency for two or more alleles present on the same chromosome to 
occur together in a population due to their close physical proximity (Ardlie et al., 2002). 
Regions of linkage disequilibrium are defined by recombination hotspots. Each region of 
linkage disequilibrium (referred to as a haplotype block) will include a number of 
alternate haplotypes – if the region of linkage disequilibrium is very high then there will 
be two common haplotypes (representing the alternate alleles) and one or more minor 
haplotypes (Hey, 2004; Ke and Cardon, 2003). Since the location and allele frequency of 
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all common SNPs across the human genome are known, the identification of a haplotype 
by tagging SNPs allows for the GWAS to map phenotypes to specific loci across the 
human genome (Bush and Moore, 2012). 
 It may be that the tagging SNP(s) itself results in a functional change to a gene, or 
alternatively another SNP that is on the same haplotype and in linkage disequilibrium 
with the tagging SNP is the true functional SNP (Bush and Moore, 2012; Liu and Lin, 
2005). The identification of the true causal SNP is the biggest challenge for biologists in 
the post-GWAS phase of a genetic study. 
Such genetic variants influence the expression of a particular phenotype by altering the 
function of the product of the gene of interest. Alternatively, if the variation is within a 
regulatory region, this may alter the level of expression of the gene product. Such loci 
which consist of SNPs that influence gene expression are called expression quantitative 
trait loci (eQTL), and are found in the intronic or intergenic regions of the gene where 
they alter the activity of cis-regulatory DNA elements (Pare, 2012). 
The integrated input of many cis-regulatory elements such as promoters, promoter-
proximal elements, and a great number of cis-regulatory modules that are localized at 
greater distances from the transcription start sites (TSSs) of genes such as enhancers 
(Bulger and Groudine, 2011; Levine, 2010), silencers (Ayer and Benyajati, 1990; 
Petrykowska et al., 2008; Vokes et al., 2008), insulators (Gaszner and Felsenfeld, 2006), 
and tethering elements (Calhoun et al., 2002; Ohtsuki et al., 1998; Spitz and Furlong, 
2012) regulate changes to gene transcription and expression that accompanies processes 
such as differentiation, proliferation and the execution of specialized cellular function 
(Nerlov, 2007). This precise regulation is vital for development, differentiation and 
homeostasis (Bulger and Groudine, 2010). Among the above mentioned regulatory 
sequences, enhancers and their associated transcription factors (TFs) play a major role in 
the initiation of gene expression (Spitz and Furlong, 2012). 
1.7. Enhancers and their Characteristics 
Enhancers are small segments of regulatory DNA that are dispersed throughout the 
genome and act as operational platforms to recruit TFs through short, specific DNA 
sequences (motifs) that stimulate gene transcription (Brazel and Vernimmen, 2016; Luo 
and Lin, 2016; Spitz and Furlong, 2012) independently of their orientation, position and 
distance to a promoter (Andersson et al., 2015; Banerji et al., 1981; Brazel and 
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Vernimmen, 2016; Fromm and Berg, 1983; Kim and Shiekhattar, 2015; Moreau et al., 
1981). Consequently, enhancers are defined by a number of characteristics that allow 
them to achieve their functions. 
First, enhancers must contain clusters of transcription factor binding sites (Gotea et al., 
2010; Plank and Dean, 2014; Shlyueva et al., 2014). Second, in order to bind transcription 
factors, an open conformation of chromatin where DNA is accessible is required 
(Heintzman et al., 2007; Shlyueva et al., 2014). Access of TFs to promoters and enhancers 
is therefore regulated by chromatin remodelling such that depletion of nucleosomes at 
regions of enhancers results in DNA hypersensitivity to DNase I treatment (Khoueiry et 
al., 2010). Third, histone tails within nucleosomes at the enhancer region must have 
enhancer-specific patterns of post-translational modifications such that dynamic and cell-
type specific patterns of histone remodelling characterize promoters (both inactive and 
active), transcribed genes (Barski et al., 2007; Kolasinska-Zwierz et al., 2009; Mikkelsen 
et al., 2007), and cis-regulatory elements (Ernst et al., 2011; Heintzman et al., 2009). For 
example, both histone H3 lysine 4 mono-methylation (H3K4me1) and H3 lysine 27 
acetylation (H3K27ac) are cis-regulatory elements-associated modifications where 
H3K27ac is correlated with enhancer activity (Bonn et al., 2012; Creyghton et al., 2010; 
Rada-Iglesias et al., 2011), while the presence of H3K4me1 in the absence of H3K27ac 
is an indication of enhancers that are in a poised state (Rada-Iglesias et al., 2011; Spitz 
and Furlong, 2012). 
Emerging evidence suggests that genetic alterations of enhancers contribute to disease 
progression (Doan et al., 2016; Jager et al., 2015; Liu et al., 2017; Pasquali et al., 2014). 
Alternate alleles of common and rare SNPs in enhancer sequences contribute to what is 
known as “enhanceropathies” (Brazel and Vernimmen, 2016; Smith and Shilatifard, 
2014). SNPs in enhancers and epigenetic changes associated with genetic changes in an 
enhancer have been strongly correlated with disease risk in many cases (Andersson et al., 
2014; Brazel and Vernimmen, 2016; Consortium, 2012; Liu et al., 2013; Shenker et al., 
2013). SNPs and small insertions or deletions (indels) could lead to a gain of a de novo 
enhancer or loss of an existing enhancer, through a change to the transcription factor 
binding (Mansour et al., 2014). SNPs identified by GWAS are predominantly located 
outside of the protein-coding regions of the human genome (Consortium, 2012; Genomes 
Project et al., 2010; Maurano et al., 2012) and map to tissue specific enhancers that have 
recently been annotated by epigenomic profiling (Akhtar-Zaidi et al., 2012; Andersson et 
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al., 2014; Corradin et al., 2014; Ernst et al., 2011; Hazelett et al., 2014; Maurano et al., 
2012; Pasquali et al., 2014). More than 80% of genetic variants associated with complex 
traits were observed in noncoding regions (Maurano et al., 2012) such that disease-
associated variants are significantly enriched in enhancer regulatory elements which 
regulate target genes via long range chromatin interactions (Farh et al., 2015). 
1.8. COPD-GWAS identify FAM13A 
 
Figure 1.6: Manhattan plot of lung function GWAS associations. Shown is the distribution 
of lung function GWAS associations according to log10 of the p-value of every association 
as a function of chromosomal locus. Horizontal line indicates significance threshold of p-
value = 1x10-8. Underlined chromosome numbers indicate chromosomes with highest 
association values. 
GWAS have identified a large number of COPD-associated genetic-risk loci across the 
genome (Figure 1.6), including transforming growth factor β1 (TGFB1) and DECORIN 
(van Diemen et al., 2006), tumor necrosis factor α (TNF-⍺) (Sakao et al., 2001), 
microsomal epoxide hydrolase 1 (Park et al., 2005), and ADAM33 (Gosman et al., 2007). 
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However, the contributions of genetic variants in these genes to COPD development are 
not definitive and meta-analysis results have been contradictory. 
Few loci have been reproducibly identified as COPD-susceptibility genes, and include 
Hedgehog interacting protein (HHIP) (Van Durme et al., 2010), iron responsive element 
binding protein 2 (IREB2) (DeMeo et al., 2009), and family with sequence similarity 13 
member A (FAM13A) (Hobbs et al., 2017) which are among the first identified COPD 
GWAS genes. 
Single nucleotide polymorphisms (SNPs) that are strongly and reproducibly associated 
with COPD are located within a FAM13A intron at locus 4q22.1 (Berndt et al., 2012) 
downstream of an exon encoding a Rho GTPase-activating protein (RhoGAP) domain 
(Cho et al., 2010; Cohen et al., 2004) (Figure 1.7). These polymorphisms are located 
within a region showing high linkage disequilibrium such that the intron may be in 
linkage disequilibrium with the RhoGAP domain-coding exon. However, the intron does 
include highly conserved sequences that are associated with several epigenetic histone 
modifications that mark regions of transcriptional regulatory activity (Hon et al., 2009), 
suggesting the presence of a regulatory element. Therefore, results of COPD GWAS 
might be identifying a regulatory sequence in the FAM13A intron, or a coding variant in 
the RhoGAP domain-coding exon of the same gene. 
SNPs rs2013701, rs2904259 and rs4693980, located directly within the putative 
regulatory element in the FAM13A intron (Figure 1.7), have been identified by a GWAS 
identifying risk loci for spirometric measures among smokers of both European and 
African ancestry (Lutz et al., 2015). This study identified associations with spirometric 
measures (post-bronchodilator FEV1 and FEV1/FVC) in 9919 current and former 
smokers in the COPDGene study (6659 non-Hispanic Whites and 3260 African 
Americans) with pulmonary function ranging from normal to severely impaired. Meta-
analyses of FEV1 and FEV1/FVC was also conducted in the combined cohorts of 
COPDGene, ECLIPSE, and GenKOLS. 
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Figure 1.7: Location of FAM13A SNPs identified in published GWAS. Shown in blue is 
FAM13A splice variants, and in green published GWAS SNPs within FAM13A. 
Little is known about FAM13A (also known as FAM13A1) function, although it may have 
a role in Rho-GAP signal transduction (Corvol et al., 2014). RhoGAP domains catalyze 
the hydrolysis of GTP bound to a GTPase such as Rho, Rac and/or Cdc42, resulting in 
the regulation of cell cytoskeletal organization, growth, differentiation, neuronal 
development and synaptic functions (Moon and Zheng, 2003; Peck et al., 2002). 
Additionally, FAM13A was recently found to play a role in regulating CPT1A expression, 
a key enzyme that controls fatty acid oxidation in mitochondria, through an intermediary 
protein, SIRT1 such that increased expression of FAM13A leads to an increase in fatty 
acid oxidation and subsequent increases in ROS in response to cigarette smoke (Jiang et 
al., 2017). 
Gene expression analyses of FAM13A in cell lines from different tissues (not including 
the lung) have demonstrated a consistent increase in its levels in response to hypoxia (Chi 
et al., 2006). Additionally, an increase of FAM13A in respiratory epithelial cells has been 
observed during differentiation into pulmonary type II cells in vitro (Wade et al., 2006) 
and between mild to severe cystic fibrosis patients (Wright et al., 2006). Furthermore, 
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loss of function studies showed protection against emphysema in FAM13A null mice 
(Jiang et al., 2016). It has been repeatedly identified as a significant locus in a number of 
genome-wide (or exome-wide) studies of COPD and its related phenotypes (Cho et al., 
2010; Cho et al., 2014; Hancock et al., 2012; Hobbs et al., 2017; Kim et al., 2015; Pillai 
et al., 2009; Wain et al., 2017). 
A recent publication shows that FAM13A promotes the degradation of β-catenin (Jiang et 
al., 2016), the major component of the adherens junctions and a key part of the Wnt/β-
catenin signalling pathway. Given that airway epithelium repair is dysregulated in COPD 
patients (Berndt et al., 2012; Milara et al., 2013), and that the Wnt/β-catenin pathway is 
down-regulated in the epithelium of human COPD lungs (Wang et al., 2011), it is possible 
that genetic variants in FAM13A increase its expression or function, leading to post-
translational decrease in the Wnt/β-catenin pathway, resulting in increased epithelial 
permeability. One possible hypothesis is that COPD risk-associated alleles in FAM13A 
are located in regulatory elements responsive to IFN-γ, the main TH1 inflammatory 
cytokine elevated in COPD. 
1.9. Hypothesis and aims 
In summary, COPD is an incurable disease characterized by ongoing processes of 
inflammation and repair of the pulmonary epithelium. The dysregulation of these 
mechanisms, including EMT, leads to disease progression. EMT is promoted by the 
regulation of β-catenin, a protein that maintains epithelial integrity and whose stability is 
regulated by FAM13A, a COPD-susceptibility gene identified by multiple genome-wide 
association studies (GWAS). However, the mechanism of FAM13A regulation remains 
unknown. In the work presented in this thesis, we show that preliminary analysis of 
COPD-associated SNPs suggests the existence of a possible enhancer within a FAM13A 
intronic region and hypothesize that its activity increases the transcription of FAM13A in 
response to IFN-γ, a major component of the inflammatory environment characteristic of 
COPD pulmonary epithelial tissue. The consequent decrease in EMT through FAM13A 
promoted degradation of β-catenin, particularly in the context of IFN-γ-induced injury 
and apoptosis, disrupts the integrity of the epithelial barrier through structural 
remodelling, resulting in an increasingly aggressive inflammatory response due to 
increased susceptibility to bacterial and viral infections. The aim of this project is to study 
the IFN-γ-dependent regulation of both FAM13A and the identified putative enhancer by 
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combining in silico and in vitro approaches. This will allow a better understanding of the 
regulation of FAM13A in the context of COPD. 
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2. Methodology 
2.1. Bioinformatics 
2.1.1. Data 
The NHGRI GWAS catalog (Hindorff et al., 2009) was used to obtain a list of GWAS 
associations. LDlink version 3.0 (Machiela and Chanock, 2015) was used to obtain both 
proxy SNPs and pairwise linkage disequilibrium data for Northern European populations. 
The UCSC genome browser (Human Feb. 2009 GRCh37/hg19 assembly) (Casper et al., 
2018; Kent et al., 2002) was used to display ENCODE annotation data (H3K27ac and 
DNase I hypersensitivity) (Rosenbloom et al., 2013) as well as DNA conservation 
(Blanchette et al., 2004) and GERP(Cooper et al., 2005; Davydov et al., 2010) data. 
Furthermore, the UCSC genome browser was used to download Histone Modifications 
by ChIP-seq, DNase I Hypersensitivity by Digital DNase I and DNase I Digital Genomic 
Footprinting data (Sabo et al., 2004; Sabo et al., 2006). Downloaded data was visualized 
using the Sushi.R package (Phanstiel et al., 2014) within the R computing environment. 
JASPAR (Khan et al., 2018) was used to obtain transcription factor binding motifs. 
3DSNP was used to visualize 3D chromatin interactions (Lu et al., 2017). 
2.1.2. Annotation 
2.1.2.1. Lead and proxy SNPs 
GWAS associations in the 4q22.1 locus were downloaded from the NHGRI GWAS 
catalog (Hindorff et al., 2009) and resulted in 315. These associations were then filtered 
for disease/trait to obtain 161 associations related to COPD, chronic bronchitis, 
pulmonary function, and lung cancer. These were then further filtered for associations in 
FAM13A to obtain 76 SNPs defined as lead SNPs. Next, proxy SNPs, SNPs that are in 
strong pairwise LD (r2>0.8), for all lead SNPs in the Northern European populations were 
obtained using LDlink (Machiela and Chanock, 2015). An LD heat map of pairwise 
comparisons of the resulting 111 total SNPs (lead and proxy) was then generated using 
LDlink (Machiela and Chanock, 2015) and the R computing environment. 
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2.1.2.2. JASPAR 
JASPAR (Khan et al., 2018) was used to obtain transcription factor binding motifs with 
84% certainty threshold. The motif representation in figure 3.10 was created using 
JASPAR(Khan et al., 2018). 
2.1.2.3. 3DSNP 
3DSNP (Lu et al., 2017) was used to analyse the subset of total (lead and proxy) SNPs 
within the identified putative enhancer region. The circos plot in figure 3.11 was taken 
directly from 3DSNP. 
2.2. Cell Culture 
Cells from both the human lung adenocarcinoma cell line A549 (ATCC® CRL-185TM) 
and the normal lung bronchial epithelial cell line BEAS-2B (ATCC® CRL-9609TM) 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) supplemented 
with 10% fetal bovine serum (FBS) (Gibco) and the antibiotic-antimycotic penicillin-
streptomycin-amphotericin B (PSF) (Gibco); and incubated at 37ᵒC in a humidified 
atmosphere containing 5% CO2. 1x106 A549 or BEAS-2B cells were seeded in T75 flasks 
and cultured for 3 days or until 80% confluent between each passage. Only cells between 
passage numbers 1 and 10 were used. 
2.3. Reverse Transcriptase Quantitative PCR (RT-QPCR) 
A549 and BEAS-2B cells were seeded in a 12-well plate at a density of 1.5 x10
5 
cells per 
well and incubated at 37°C with 5% CO2 for 48 hours or to reach 90% confluence. Cells 
were then treated with IFN-γ [10 ng/mL] for 0.5, 2, 6 or 24 hours. The expression of 
selected genes (Table 2.1) was then quantified using real time quantitative PCR (qPCR). 
To achieve this, RNA was extracted using the Isolate II RNA mini kit (BIO-52072, 
Bioline) according to the manufacturer’s protocol. The resulting RNA product was then 
quantified using the NanoDrop spectrophotometer and stored at -80°C. 
cDNA was then synthesized using the SensiFASTTM cDNA synthesis kit (BIO-65053, 
Bioline), such that each reaction mixture contained 500 ng of the extracted RNA, 4µL of 
5x TransAmpTM buffer, 1µL of reverse transcriptase and nuclease free water to reach a 
final volume of 20µL. The thermocycling parameters used are as follows: 1 cycle of 25°C 
34 
 
for 10 minutes, 42°C for 15 minutes, followed by 85°C for 5 minutes. Synthesized cDNA 
was diluted 5 folds with nuclease free water and stored at -20°C. 
Finally, reaction mixtures composed of 2µL of the diluted cDNA, 5µL of 2x 
SensiFASTTM SYBR Lo- ROX mix (BIO-94005, Bioline), a final concentration of 
0.25µM primers (Table 2.1), and nuclease free water to reach 10µL were cycled using the 
ABI 7500 FAST system (Applied Biosystems) with the following conditions: 1 cycle at 
95°C for 20 seconds, 40 cycles at 95°C for 3 seconds, 60°C for 30 seconds and 1 cycle at 
95°C for 15 seconds, 60°C for 1 minute, 95°C for 15 seconds, 60°C for 15 seconds. The 
nuclear transcription factor Y, subunit beta (NFYB) gene was used to normalize gene 
expression. The average of 2
-ΔCt
 calculated for individual experiments was then used to 
calculate fold change in expression using the formula: 
fold change in expression = meantreated/meanuntreated. 
Table 2.1: List of RT qPCR primers and their respective sequences. 
Gene Primer Primer sequence 
FAM13A_1 
FAM13A_1_FWD GGAGCTCTAGCCATCTGTCAA 
FAM13A_1_REV CCTTCTGTTCATTTAATGGCACT 
FAM13A_2 
FAM13A_2_FWD GCAGCCTCGATTCATTCAAC 
FAM13A_2_REV GGTGTCTGGCAGCTCTTTTA 
CDH1 
CDH1_FWD CCTGAGCTCCCTGACAAAAA 
CDH1_REV CCACCAGGGTATACGTAGGG 
CDH2 
CDH2_FWD GGACCGAGAATCACCAAATG 
CDH2_REV AGATCTGCAGCGTTCCTGTT 
NFYB 
NFYB_FWD AGATTGCAAAAGATGCCAAAG 
NFYB_REV CGTTTCTCTTGATGGCACCT 
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2.4. Construction of FAM13A Enhancer Luciferase Reporter Plasmids 
Primers were designed to target and amplify a large putative enhancer sequence 1074bp 
long (Sigma-Aldrich) (Table 2.2) for cloning into a pGL3-promoter vector (Figure 2.1). 
To ensure the insertion of the amplified enhancer region in the correct orientation into the 
vector (Figure 2.1), a KpnI restriction site was added to the 5’ end of the forward primer 
and BglII restriction site to the 5’ end of the reverse primer (Table2.2). 
Genomic DNA (gDNA) was extracted from A549 and BEAS-2B cells using the Isolate 
II genomic DNA kit (BIO-52066, Bioline) according to the manufacturer’s protocol. The 
isolated gDNA was quantified using the NanoDrop spectrophotometer. 
PCR was performed using Phusion High Fidelity DNA Polymerase (M0530S, New 
England BioLabs) and the Veriti Thermal Cycler (Applied Biosystems). The PCR 
reactions contained 10µL of 5× Phusion HF Buffer, 0.5µL of enzyme, 1µL of dNTP mix 
at 10mM, 2.5µL of each forward and reverse primer mixes at a concentration of 10µM 
for each primer, 50 ng of gDNA template, 1.5µL of DMSO and nuclease-free water to 
make a final volume of 50µL. 
Table 2.2: FAM13A enhancer fragment primers (5’to3’) with added restriction site sequences 
for KpnI and BglII These sequences are also found in the multiple cloning site of the vector 
pGL3-promoter (Fig. 2.1) and allow the directional cloning of the enhancer amplicons. 
F13A_1074ENH_KpnI_FWD CGAGAGGTACCGCTGCAAATTTCCCTGGAGT 
F13A_1074ENH_BglII_REV GCTCGAGATCTGATGTGGACGTTGCAGTGAG 
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Figure 2.1: Map of the pGL3-promoter vector The Luciferase Cloning Vector pGL3-Promoter. 
The figure shows important details of the plasmid: luc+, cDNA encoding the modified firefly 
luciferase; Ampr, gene conferring ampicillin resistance in E. coli; f1 ori, origin of replication 
derived from filamentous phage; ori, origin of plasmid replication in E. coli. Arrows within 
luc+ and the Ampr gene indicate the direction of transcription; the arrow in f1 ori indicates 
the direction of ssDNA strand synthesis. Also shown is the multiple cloning site (boxed 
sequences 5 to 36) that includes recognition sites for multiple restriction endonucleases. 
The FAM13A enhancer is inserted upstream of the SV40 promoter into the cloning site 
determined by the KpnI and BglII restriction endonuclease recognition sites.  
Adapted from pGL3 luciferase reporter vectors technical manual (Promega). Figure 3. 
The thermal cycling profile was as follows: 
1 cycle of 98ᵒC for 30 seconds of initial denaturation followed by 5 cycles of 98ᵒC for 10 
seconds for denaturation of nucleic acids, 64 ᵒC for 30 seconds for annealing of primers, 
and 72ᵒC for 30 seconds for extension; this is then followed by 30 cycles of 98ᵒC for 30 
seconds for denaturation of nucleic acids, 60ᵒC for 30 seconds for annealing of primers, 
and 72ᵒC for 30 seconds for extension. 
Agarose gel electrophoresis of the amplified products, to confirm the precise 
amplification of the enhancer region, was done by taking 5µL aliquot of each sample and 
loading onto 1.5% agarose gel containing Sybr Safe DNA Gel Stain (Thermo Fisher 
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Scientific) and photographed using Gel Doc™ EZ System (Bio-Rad). Each gel included 
a 1Kb ladder. 
PCR products were then column purified using the Isolate II PCR and Gel kit (BIO-
52059, Bioline) and were quantified using the NanoDrop spectrophotometer. 
To insert the putative enhancer fragment into the pGL3-promoter vector, the restriction 
endonuclease recognition sites were cleaved in both the putative enhancer fragment and 
the pGL3-promoter by double digestion with BglII and Acc65I, an isoschizomer of KpnI. 
The reaction mixture contained 1µL (10u/µL) of BglII (R0144S, New England BioLabs), 
1µL (10u/µL) of Acc65I (R0599S, New England BioLabs) and, 5µL of 10x Buffer 3.1 
(B7203S, New England BioLabs) and nuclease free water to reach a final volume of 50µL 
and incubated at 37°C for 1 hour. 
The digestion reaction was then heat inactivated by incubation at 65°C for 20 minutes. 
1.5% agarose gel electrophoresis was then used to verify the successful digestion. 
This was the followed by a ligation reaction containing 32.15 ng of the digested putative 
enhancer fragment, 50 ng of the digested pGL3 plasmid (which results in the 
recommended 1:3 DNA: Vector ratio), 1µL of T4 DNA ligase (M0202S, New England 
BioLabs), 5µL 4x T4 DNA ligase buffer (B0202S, New England BioLabs), and nuclease 
free water to reach a final reaction volume of 20µL. In parallel, a control ligation was 
performed, containing only the linearized pGL3 plasmid. Ligations were then placed in 
the Veriti Thermo-cycler (Applied Biosystems) and incubated overnight at 16°C. 
Ligations were confirmed by electrophoresis of samples on a 1% agarose gel and was 
successful if single bands appeared at approximately 6Kb. 
The successful ligation, which resulted in the pGL3-FAM13Aenh reporter construct, was 
that used to transform E. coli. 25µl of ice-cold α-Select chemically competent cells (BIO-
85025, Bioline) were transformed with 5µL of the ligated plasmid/enhancer fragment and 
incubated on ice for 30 minutes. Samples were then heat-shocked at 42°C for 45 seconds 
and returned immediately to ice for at least 2 minutes. 250µL of LB-broth (without 
ampicillin) was added to the cell suspension and incubated at 37°C for 30 minutes with 
shaking. LB-agar plates containing ampicillin were then inoculated with 150µL of the 
cell suspension and evenly distributed on the plate using a disposable cell spreader. Plates 
were then incubated overnight at 37°C. 
Single colonies were then screened for the presence of the enhancer fragment. This was 
achieved via PCR. Using a pipette tip, a small portion of every colony was picked and 
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placed in 20µL of Milli-Q® water. PCR reactions contained 2.5µL of 10µM FAM13A 
primer working stock (Table 2.2), 12.5µL of AmpliTaq Gold® 360 Master Mix 
(4398876, Applied Biosystems) and adjusted to a final volume of 25µL with nuclease 
free water. The cycling parameters were; 1 cycle at 95°C for 5 minutes, 30 cycles at 95°C 
for 30 seconds, 65°C for 30 seconds and 72°C for 2 minutes; followed by a final extension 
at 72°C for 5 minutes for 1 cycle. A 1.5% agarose gel was run to confirm the presence of 
the cloned FAM13A enhancer fragment. Positive colonies were then expanded in 2mL of 
LB-broth cultures containing 1x ampicillin in a 37°C shaking incubator overnight. 
Plasmids were purified using the Monarch® Plasmid miniprep kit (T1010S, New England 
BioLabs) according to manufacturer’s instructions. Purified plasmids were quantified 
using the NanoDrop spectrophotometer with plasmids stored at -20°C. 
2.5. Luciferase Assay 
A 24-well plate was seeded with 1x105 cells per well of either the A549 or BEAS-2B cells 
and left overnight in an incubator at 37°C in order to adhere to the plate. These cells were 
then transfected with the luciferase-containing reporter vector using Lipofectamine 3000 
according to manufacturer’s protocol. The transfection medium was added to the cells 
and consisted of 1.5µL of Lipofectamine™ 3000 (L3000008, ThermoFisher Scientific), 
1µL of P3000™, 700 ng of pGL3-FAM13Aenh reporter construct or pGL3 empty vector, 
50 ng of β-galactosidase reporter plasmid and serum free DMEM medium to make 50µL. 
The cells were incubated with the transfection medium for 8 hours at 37°C, after which 
the transfection medium was removed, and IFN-γ [10 ng/mL] diluted in DMEM growth 
medium supplemented with 5% FCS and no PSF was added to the cells for 0.5, 2, 6 and 
24 hours at 37°C. 
Both the A549 and BEAS-2B cells were harvested by the addition of 100µL of 1x reporter 
lysis buffer (E4030, Promega) after washing twice with PBS. The cells were incubated 
on ice for 5 minutes with the lysis buffer and the cell lysate was then transferred to a 
1.5mL Eppendorf tube and centrifuged at 16,000xg for 5 minutes at 4°C to remove 
cellular debris. 25µL of the cell lysate was then combined with 25µL of the Beta-GLO 
normalizing reagent (E4720, Promega) in a black, clear bottom 96-well plate and 
incubated for 30 minutes at room temperature protected from light. 20µL was then added 
to 100µL of the luciferase reagent (E1500, Promega) and the samples were then 
immediately analyzed in the FluoSTAR optima plate reader. Normalized relative 
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luciferase activity of the pGL3-FAM13Aenh reporter construct was calculated using the 
empty pGL3 reporter plasmid. 
2.6. Western Blot 
A549 and Beas-2b cells cultured in 6-well plates and treated with IFN-γ [10 ng/mL] for 
0.5, 2, 6 or 24 hours were placed on ice and their media was aspirated. Each well was 
washed twice with 1mL of PBS (with protease inhibitor) after which the cells lysed with 
RIPA lysis and extraction buffer (89988, ThermoFisher Scientific) (with protease 
inhibitor), scraped and collected into 1.5 mL Eppendorf tubes. This was followed by 
centrifugation for 5 minutes at 300xg. The supernatant was then discarded, and the pellet 
of whole cell lysate was resuspended in 150µl of buffer A. 
Using the NanoDrop spectrophotometer, protein concentrations were determined for 
every sample. 30 µg of each sample was loaded into a 12% Mini-PROTEAN® TGXTM 
Precast Protein Gel (Bio-Rad) and separated by SDS polyacrylamide gel electrophoresis 
(PAGE). The proteins were then transferred onto a nitrocellulose membrane using the 
Trans-Blot® TurboTM Transfer System (Bio-Rad) at a constant 0.3 A for 1 hour. The 
nitrocellulose membrane was then blocked for 30 minutes in blocking buffer (5% skim 
milk in 1% TBS/Tween-20). After this, the membrane was incubated overnight at 4℃ 
with anti-FAM13A antibody (Abcam, ab204425), anti-β-catenin (Abcam, ab32572) or 
anti-TGF-β2 (Abcam, ab36495). After 16 hours, the membrane was washed using 1x 
TBS/0.1%Tween-20 at room temperature with gentle shaking for 20 minutes. This 
washing step is repeated an additional 2 times followed by incubation with goat anti-
rabbit IgG (H+L)-HRP conjugate (1706515, Bio-Rad) at a 1:10000 dilution in blocking 
buffer at room temperature, with gentle shaking for 1 hour. Once the incubation was 
completed, the membranes were washed 3 times with 1xTBS/0.1%Tween-20 for 20 
minutes each, at room temperature with gentle shaking. Finally, the image was developed 
by incubating the membrane with ClarityTM Western ECL Substrate (1705061, Bio-Rad) 
according to the manufacturer’s protocol and imaged using the C-Digit ® Blot Scanner 
(Li-Cor) imager.  
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Table 2.3: Composition of Western Blot buffer. 
Solution 
Final Concentrations 
Buffer A 
Tris-HCl pH 8.0 
[1M] 
10mM 
NaCl [5M] 10mM 
EDTA pH 8.0 
[0.5M] 
0.1mM 
Protease Inhibitor 1x 
 
2.7. Immunofluorescence 
A549 and BEAS-2B cells were seeded into 8-well chamber slides at a density of 
1x105cells/well. Following treatment with IFN-γ [10 ng/mL] for 0.5, 2, or 6 hours, cells 
were washed once with PBS (250 µl/well). 4% formaldehyde was added (250 µl/well) 
for 10 minutes to fixate the cells. The cells were then washed 3 times with 250 µl/well of 
0.01% Triton X-100 (diluted in PBS). Four drops of Image-iTTM FX Signal Enhancer 
(I36933, Thermo Fisher Scientific) was added to each well and incubated at room 
temperature for 30 minutes, protected from light. The cells were then washed 3 times with 
250 µl/well of 0.02% Triton X-100 (diluted in PBS). After this, the cells were incubated 
overnight at 4℃ with 100 µl/well of anti-STAT1 (phospho S727) antibody (Abcam, 
ab109461) or anti-STAT3 (phospho Y705) antibody (Abcam, ab76315) diluted in 
blocking buffer (1% BSA, 0.01% Triton X-100, 5% FCS in PBS). 
Excess antibody left overnight was aspirated and each well was washed 3 times with 
0.01% Triton X-100. 100µl/well of secondary antibodies Alexa Flour® 488 goat anti-
rabbit IgG (A3628, Molecular Probes by Life TechnologiesTM) and Alexa Flour® 555 
goat anti-mouse (A31622, Molecular Probes by Life TechnologiesTM) (1:1000 dilution in 
blocking buffer) was then added and incubated at 4℃ for 1 hour, protected from light. 
Following incubation, each well was washed 3 times with 100µl of 0.01% Triton X-100. 
Hoechst 33342 (I35105, Molecular Probes by Life TechnologiesTM) was then diluted 
1:1000 in blocking buffer of which 100µl was added to each well. The chamber slide was 
then incubated at room temperature for 15 minutes, protected from light. After this, the 
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wells were washed 3 times with 0.01% Triton X-100. Finally, the chambers were removed 
according to manufacturer’s protocol. One drop per well of Prolong® Gold antifade 
(P36934, Molecular Probes by Life TechnologiesTM) reagent was used to mount the 
slides. 
Images were taken with Leica Las X version 3.0.4 obtained from Leica Microsystems. 
2.8. Chromatin Immunoprecipitation Assay (ChIP Assay) 
2.8.1. Cell Harvesting and Cross-linking 
10 cm2 plates were seeded with 3x106 cells per dish and left to incubate for 48 hours at 
37℃ to reach 90% confluence. These cells were then treated with IFN-γ [10 ng/mL] for 
0.5, 2, 6 or 24 hours. The cells were rocked gently at room temperature for 6 minutes after 
formaldehyde (37% molecular biology grade, Sigma F8775) was diluted in the culture 
media to 1%. To terminate fixation, 1.25M Glycine (Sigma) was added to the culture 
media to a final concentration of 125mM and incubated at room temperature for 5 
minutes. The media was then removed, and the cells were washed twice with 10mL of 
PBS with 1x protease inhibitor. Following this, 2mL/10cm2 dish of 0.25% Trypsin-EDTA 
(Gibco) was added to the cells and rocked gently at room temperature for 5 minutes. 
2.8.2. Chromatin Extraction and Sonication 
The Trypsin-EDTA was aspirated and replaced with 3mL/10cm2 dish of cell membrane 
lysis buffer with 0.5% Triton X-100 and 1x protease inhibitor. The cells were scraped and 
collected in 50mL Falcon tubes. The tubes were incubated on ice for 30 minutes with 
vortexing every 10 minutes to facilitate lysis. The cell suspension was then gently passed 
4 times through a 21-gauge need to create a single cell suspension. Following this, the 
tubes were centrifuged at 850xg for 5 minutes at 4°C. The supernatant was discarded, and 
the nuclei were then resuspended in 300µL of nuclear lysis buffer and incubated on ice 
for 30 minutes with vortexing every 10 minutes to facilitate lysis. Finally, nuclear lysates 
were transferred to 1.5mL Eppendorf tubes for sonication. 
The chromatin was sheared by sonicatation using a Branson Digital Sonifier with a 
3.2mm tip at 30% amplitude for 15 seconds ON and 59 seconds OFF for 60 cycles. 
Sheared chromatin was then centrifuged at 14000xg for 5 minutes at 4℃ and the 
supernatant was transferred to a new 1.5mL Eppendorf tube. 45µL of the supernatant was 
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then aliquoted as an input sample, 20µL was removed from the chromatin suspension to 
be used as a sonication control, and the remaining sonicated chromatin was aliquoted at 
1x106 cells/aliquot and frozen at -80℃. 
Table 2.4: Composition of lysis buffers. 
Solution 
Final Concentrations 
Cell Lysis Buffer Nuclei Lysis Buffer 
Tris-HCl pH 8.0 [1M] 20mM 50mM 
KCl [3M] 85mM - 
NP-40 10% 0.5% - 
EDTA pH 8.0 [0.5M] - 10mM 
SDS 10% - 1% 
 
2.8.3. Verification of Chromatin Fragment Length 
To the sonication control, 180µL of 5M NaCl and 2.5µL of proteinase K were added and 
the mixture was incubated at 65℃ overnight. Following the incubation period, the sample 
was treated with RNase A at 37℃ for 30 minutes. The sheared DNA was then column 
purified using Bioline Isolate II PCR and Gel kit (Bioline, BIO-52059) and run on a 2% 
agarose gel. Sonication fragments were visualized and verified to be between 200 and 
500 bp. After this, the frozen aliquots were thawed on ice and diluted to 1mL in immune-
precipitation (IP) buffer. 
2.8.4. Immunoprecipitation (IP) 
3 µg of the test antibody [anti-H3K4me3 (Abcam, ab8580), anti-STAT-1 (Abcam, 
ab180814), and anti-STAT1 (phospho S727) (Abcam, ab109461)] was then added to IP 
buffer diluted chromatin aliquots. The samples were incubated overnight at 4℃ with 
rotation. 
Every ChIP (1x106 cells) requires 20µL of the Magna ChIP Protein A/G magnetic beads 
(Merck, 16-663), which were washed twice with 1mL of IP buffer and recovered by the 
DynaMag magnetic particle concentrator (Invitrogen, 123.21D) prior to use. For each 
ChIP sample, recovered beads were then resuspended in 300µL of IP buffer. The 
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antibody/chromatin samples were centrifuged at 14000xg for 10 minutes at 4℃ to remove 
insoluble material, and the supernatant was then transferred to the bead pellet. This was 
then incubated at 4℃ for 1 hour with rotation. After incubation, the 
bead/antibody/chromatin complex was washed 3 times with 1mL Low salt buffer, 1 time 
with 1mL High salt buffer, and 1 time with 1mL TE buffer. 
2.8.5. Elution and Reverse Cross-linking 
Following the final TE wash, the cross-linked chromatin was eluted from the beads by 
adding 100µL of elution buffer to the chromatin/bead mixture and incubated at 30℃ for 
15 minutes, with brief vortexing every 5 minutes. The beads were pelleted by 
centrifugation at 2000 rpm for 1 minute and the supernatant, which contains the eluted 
cross-linked chromatin, was then transferred to a new 1.5mL Eppendorf tube. The eluted 
chromatin and the input chromatin sample were reverse cross-linked by adding 8µL of 
5M NaCl and 2µL of 10 mg/mL RNase A and incubating the mixture at 65℃ overnight 
with shaking.  
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Table 2.5: Composition of immunoprecipitation buffers. 
Solution 
Final Concentration 
IP Buffer 
Low Salt 
Buffer 
High Salt 
Buffer 
TE Buffer 
Elution 
Buffer 
EDTA pH 8.0 
[0.5M] 
1.2mM 2mM 2mM 1mM 5mM 
SDS 10% 0.01% 0.1% 0.1% - 1% 
Triton X-100 
10% 
1% 1% 1% - - 
Tris-HCl pH 8.1 
[1M] 
16.7mM 20mM 20mM 10mM - 
NaCl [5M] 167 mM 150mM 500mM - 50mM 
Protease 
Inhibitor 
1x - - - - 
Tris-HCl pH 7.5 
[1M] 
- - - - 50mM 
 
2.8.6. DNA Recovery 
After the incubation, 2µL of 20 mg/mL proteinase K was added to this mixture and 
incubated for 1 hour at 60℃ with shaking. The obtained reverse cross-linked DNA was 
then purified using the Isolate II PCR and Gel kit (Bioline, BIO-52059) and stored at -
20℃ until its analysis by RT-QPCR. 
2.8.7. ChIP-qPCR and Data Analysis 
The quantitative PCR analysis reaction mixture contained 10µL of 2x SensiFast SYBR 
Lo-ROX mix (BIO-94005, Bioline), 1.6µL of the forward and reverse primers (100µM) 
each, 2µL of the immuno-precipitated DNA, input DNA or mock DNA and adjusted to a 
final volume of 20µL with nuclease free water. Finally, the thermal cycler ABI 7500 
FAST system (Applied Biosystems) was programmed with the following parameters: 1 
cycle at 95℃ for 20 seconds and 40 cycles at 95°C for 3 seconds, 60°C for 30 seconds 
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and 1 cycle at 95°C for 15 seconds, 60°C for 1 minute, 95°C for 15 seconds, 60°C for 15 
seconds. 
Table 2.6: List of ChIP RT qPCR primers and their respective 5’ to 3’ sequences. 
Gene Primer Primer sequence 
FAM13A 
FAM13A_ChIP_FWD TGGCTCAATTCAGTCCAAGA 
FAM13A_ChIP_REV TGCCCTTACCCATGGTATTC 
 
H3K4me3 was used to normalize the expression of STAT-1 total and STAT-1 
phosphorylated and determine their fold enrichment relative to H3K4me3. The Ct values 
of each IP sample was normalized to the input to account for any differences in chromatin 
sample preparation. 
ΔCt [normalized ChIP] = (Ct[IP] – (Ct[input] – Log2(input dilution factor))) 
such that input dilution factor = amount of input chromatin/amount of total chromatin. 
 
Next, the difference between the normalized experimental sample (ES) and the control 
sample (CS) was determined such that the experimental samples refer to the samples 
immunoprecipitated with either STAT-1 total or phosphorylated and the control samples 
refer to samples immunoprecipitated with H3K4me3: 
ΔΔCt[ES-CS] = ΔCt [ES normalized ChIP] - ΔCt[CS normalized ChIP].  
The fold enrichment in occupancy was calculated by 2 (-ΔΔCt [ES-CS]). 
Finally, the input percentage was calculated according to the following formula: 
Input % = fold enrichment x 100. 
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3. Results and Discussion 
3.1. In silico identification of a putative FAM13A enhancer 
3.1.1. Introduction 
It is now apparent that many disease-associated non-coding SNPs identified in GWAS 
(Visscher et al., 2017; Yu et al., 2018) increase the susceptibility of an individual to 
particular diseases or traits by affecting enhancer function. The human genome contains 
regions of linkage disequilibrium (LD), or haplotype blocks, where alleles that are closely 
located on the same chromosome tend to occur together in a population. The mapping of 
the haplotype structure of the human genome allows the identification of causal variations 
in complex diseases (International HapMap, 2003; Nejentsev et al., 2004). Loci that 
include SNPs that influence gene expression and directly link specific risk-alleles in 
enhancers (or promoters) to changes in gene expression are known as expression 
quantitative trait loci (eQTL). The mapping of eQTLs is one of the key outcomes of 
GWAS (Brazel and Vernimmen, 2016; Pomerantz et al., 2009; Takahashi et al., 2011; 
Wasserman et al., 2010). 
3.1.2. Identification of high LD region of lung-function associated SNPs 
Most disease-associated variants identified by GWAS (about 85%) map to non-coding 
regions within the genome (Hindorff et al., 2009). Furthermore, functional non-coding 
regions such as enhancer elements, DNase hypersensitivity regions and chromatin 
modifications show significant enrichment for GWAS variants (Degner et al., 2012; 
Trynka et al., 2013; Zhang and Lupski, 2015). 
Many lung function-associated GWAS repeatedly identify SNPs within FAM13A, that 
map to regions characterized by epigenetic modifications that suggest the presence of cis-
regulatory elements. To test the hypothesis that lung function and COPD-associated SNPs 
that map to non-coding regions in FAM13A identify functional enhancers (Lutz et al., 
2015), enhancers were defined as intronic regions characterized by H3K27ac marks, 
DNase I hypersensitivity, TF binding sites and DNA conservation. 
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Using the method outlined by (Schaub et al., 2012), a lead SNP was defined as any SNP 
that has been statistically associated with a COPD or lung-function phenotype and a proxy 
SNP as any SNP that is in strong pairwise LD (r2>0.8) with a lead SNP. 
By curating the NHGRI GWAS catalog (Hindorff et al., 2009) for GWAS associations in 
the 4q22.1 locus, 315 associations were obtained. These associations were then filtered 
for disease/trait to obtain 161 associations related to COPD, chronic bronchitis, 
pulmonary function, and lung cancer. These were then further filtered for associations in 
FAM13A to obtain 76 unique lead SNPs. 
Next, for each lead SNP we determined the set of proxy SNPs in the Northern European 
populations to obtain a total of 111 SNPs that identify several COPD-associated 
haplotype blocks. An LD heat map of pairwise comparisons of the resulting 111 SNPs 
was then generated (Figure 3.1). Five main blocks of high linkage disequilibrium could 
be distinguished at genomic coordinates 89660962-89805048, 89803692-89873375, 
89874372-89901027, 89901030-89924780 and 89925700-90013347 on chromosome 4 
with respective approximate sizes of 114Kb, 71Kb, 27Kb, 24Kb and 88Kb. These blocks 
of high linkage disequilibrium will be referred to as “LD Block 1”, “LD Block 2”, “LD 
Block 3”, “LD Block 4” and “LD Block 5” respectively.  
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Figure 3.1: LD heat map of FAM13A lung function-associated GWAS SNPs and their proxy 
SNPs in the Northern European populations. Blocks of red identify areas of high linkage 
disequilibrium, indicating alleles that tend to be inherited together in a population. Numbers 
1-5 refer to LD blocks 1-5 defined in the text. 
3.1.3. Epigenetic analysis of identified high LD region 
The identified LD blocks were inspected for the presence of enhancer characteristics 
using the UCSC genome browser (Human Feb. 2009 GRCh37/hg19 assembly) (Kent et 
al., 2002).  
H3K27ac marks for 7 different cell lines from ENCODE, often found near active 
regulatory elements, were compared for the identified LD blocks (Figure 3.2). LD Block 
2 lacked any significant H3K27ac signal. Furthermore, a magnified view of each region 
covered by LD blocks 1 and 3-5 revealed normal human lung fibroblasts (NHLF) and 
normal human epidermal keratinocytes (NHEK) cell type specific H3K27ac marks only 
in LD Blocks 1 and 3 (Figure 3.3). 
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Figure 3.2: H3K27ac marks within 7 different cell lines from ENCODE at the identified LD 
Blocks in FAM13A. Numbers 1-5 refer to LD blocks 1-5 defined in the text. Images are taken 
directly from UCSC genome browser (Human Feb. 2009 GRCh37/hg19 assembly) (Kent et 
al., 2002). 
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Figure 3.3: Comparison of H3K27ac within 7 different cell lines at LD Block 1 (A), 3 (B), 4 (C) 
and 5(D) in FAM13A. Light purple and pink peaks represent H3K27ac signals in NHLF and 
NHEK cell lines respectively. Images are taken directly from UCSC genome browser (Human 
Feb. 2009 GRCh37/hg19 assembly) (Kent et al., 2002). 
Given that LD Blocks 1 and 3 but not LD Blocks 4 or 5 contained a strong H3K27ac peak 
from an epithelial cell line, LD Regions 3 and 4 were analysed in more detail for DNase 
I hypersensitivity (Figure 3.4). 
In both LD Blocks 1 and 3, DNase I hypersensitivity signals overlap with the H3K27ac 
marks. Furthermore, the DNase I hypersensitivity signal in LD blocks 1 and 3 for both 
the NHLF and the human small airway epithelial cell (SAEC) lines was comparable. 
However, due to the limitations of this project, LD block 3 was chosen for further analysis 
using data from cancerous (A549) and non-cancerous (NHLF and SAEC) lung epithelial 
cells. 
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Figure 3.4: Comparison of DNase I hypersensitivity at LD Block 1 (A) and 3 (B) in FAM13A. 
The cell lines NHLF and SAEC are normal human lung fibroblasts and small airway epithelial 
cells respectively. Images are taken directly from UCSC genome browser (Human Feb. 2009 
GRCh37/hg19 assembly) (Kent et al., 2002). 
DNase I hypersensitivity data for LD Region 3 within 3 lung epithelial cell lines, NHLF, 
SAEC and human alveolar adenocarcinoma (A549) was downloaded from the UCSC 
genome browser (Human Feb. 2009 GRCh37/hg19 assembly) (Kent et al., 2002) as 
narrowPeak (Figure 3.5) and raw signal data (Figures 3.6-3.8) and plotted. NarrowPeak 
data represents peaks of DNase I hypersensitive sites whereas raw signal data represents 
DNase I sensitivity as a continuous function using sequencing tag density. 
It was found that DNase I hypersensitivity peaks were conserved between normal and 
cancerous cell lines (Figure 3.5). Furthermore, the DNase I hypersensitivity clusters 
overlapped with H3K27ac marks in both the normal (NHLF) (Figure 3.6) and 
adenocarcinoma (A549) (Figure 3.7) cell lines. 
Although the H3K27ac signal was comparable between both the normal (NHLF) and the 
cancer (A549) cell line reaching 10 and 15 peak reads respectively, the signal strength of 
the DNase I hypersensitivity was noticeably lower in the A549 cell line than in both the 
NHLF and the SAEC cell lines reaching 15, 50 and 120 peak reads respectively (Figure 
3.8), thus reflecting lower DNA accessibility of this region in the A549 cell line compared 
to normal cell lines. 
Moreover, a cluster of positive and negative position-specific estimates of evolutionary 
constraint as calculated by GERP also characterize this region (Figure 3.9) such that 
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positive GERP scores indicate possible evolutionary constraint where fewer substitutions 
occur than an average neutral site (Cooper et al., 2005). 
 
Figure 3.5: DNase I hypersensitivity peak clusters identified in LD Block 3. The cell lines 
A549, NHLF and SAEC are lung adenocarcinoma epithelial cells, normal human lung 
fibroblasts, and small airway epithelial cells respectively. Data represents narrow peaks and 
as such represents peaks of signal enrichment based on pooled, normalized data. 
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Figure 3.6: DNase I hypersensitivity and H3K27ac ChIP-seq plot in A549 cell line at LD Block 
3. Data represents raw signal and as such represents the density of tags mapping within a 
150 bp sliding window (at a 20 bp step across the genome). 
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Figure 3.7: DNase I hypersensitivity and H3K27ac ChIP-seq plot in NHLF cell line at LD Block 
3. Data represents raw signal and as such represents the density of tags mapping within a 
150 bp sliding window (at a 20 bp step across the genome). 
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Figure 3.8: Comparison of DNase I Hypersensitivity signals at LD Block 3. The cell lines 
A549, NHLF and SAEC are lung adenocarcinoma epithelial cells, normal human lung 
fibroblasts, and small airway epithelial cells respectively. Data represents raw signal and 
as such represents the density of tags mapping within a 150 bp sliding window (at a 20 bp 
step across the genome).  
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Figure 3.9: Epigenetic marks within LD Block 3. Shown is the location of SNPs identified in 
published GWAS, H3K27ac marks, DNase I hypersensitivity clusters, conserved DNA 
sequences (green clusters), and Genomic Evolutionary Rate Profiling (GERP). 
Overall, an LD heatmap of lung-function associated GWAS SNPs and their proxy SNPs 
identified 5 blocks of high LD. Analyses of these blocks revealed that only blocks 1 and 
3 showed H3K27ac marks (often found near active regulatory elements) in epithelial cell 
lines. However, due to the limitations of the project, LD Block 3 only was analysed 
further. DNase I hypersensitivity regions were found to overlap with H3K27ac marks in 
both normal and cancer cell lines, however, the DNase I hypersensitivity signal was much 
lower in cancer cells. Additionally, the identified LD Block 3 was found to include 
regions of DNA conservation and possible evolutionary constraint as indicated by 
positive GERP scores. 
3.1.4. JASPAR 
Next, DNase I digital genomic footprinting data for LD Block 3 within SAEC was plotted. 
A DNA footprint is defined as a region protected from DNase I cleavage due to the 
binding of a transcription factor. The protected region is flanked by enhanced DNase I 
cleavage, resulting in DNase I hypersensitivity sites. 
A 240 bp region within LD Block 3 that showed a significant decrease in DNase I 
hypersensitivity signal was identified. Analysis of the DNA sequence within this region 
using JASPAR identified a STAT-1 binding site with 84% certainty (Figure 3.10). 
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Figure 3.10: DNase I digital footprint signal in SAEC at LD Block 3. Top: an expanded view 
of the DNase I hypersensitivity site in LD Block 3; Middle: a magnified view of the DNA 
footprint showing very low levels of DNase I cleavage; Bottom: identified consensus DNA 
binding motif for the transcription factor STAT-1. DNase I data represents per-base count of 
sequence reads whose 5’ end (corresponding to a DNase I-induced DNA cut) coincides with 
the given position. Sequence logo representing frequency matrix for STAT-1 is retrieved 
from JASPAR database. 
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3.1.5. Putative FAM13A enhancer interacts with FAM13A through self-looping 
Having identified a high LD block in FAM13A which displays enhancer characteristics, 
this region was investigated for DNA interactions. Protein-mediated chromatin looping 
allows the interaction between promoters and distal regulatory elements such as 
enhancers and silencers (Marsden and Laemmli, 1979; Wang et al., 2005). The 3DSNP 
database (Lu et al., 2017), which integrates data from different Hi-C datasets, 1000 
Genomes Phase 3 data (Genomes Project et al., 2015), Roadmap Epigenomics (Bernstein 
et al., 2010) and ENCODE projects (Consortium, 2012), TRANSFAC (Matys et al., 
2006) and JASPAR (Khan et al., 2018) databases, the GTEx project (Consortium, 2013) 
and the UCSC Genome Browser (Kent et al., 2002) was used to analyse LD Block 3 in 7 
different cell lines: human chronic myelogenous leukemia (KBM-7), prostate 
adenocarcinoma (LNCaP), normal human embryonic stem cells (H1-hESC), normal 
human umbilical vein endothelial cells (HUVEC), B-lymphocyte lymphoblastoid cells 
(GM12878), and fetal lung fibroblasts (IMR90). 61 SNPs within this noncoding region 
were identified, all displaying chromosome loops contained within the FAM13A gene 
(Figure 3.11) and indicating the interaction of the putative enhancer element with the 
promoter region at the 5’ end of FAM13A. 
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Figure 3.11: Circos plot of intra-chromosomal interaction between putative FAM13A 
enhancer and FAM13A promoter in 7 different cell lines. The outer circle represents 
chromatin segmentation states: Bright/Light Red: Active/weak Promoters; Purple: poised 
promoter; Orange: strong enhancer; Yellow: weak/poised enhancer; Blue: insulator; 
Dark/light Green: Strong/weak transcription; Grey: repressed chromatin. The middle circle 
shows gene locations in green; the inner circle shows the location of SNPs in red. In the 
middle of the circle is shown the start and end-points of chromosome loops, colour-coded 
for different cell lines: human chronic myelogenous leukemia [KBM-7] (red); prostate 
adenocarcinoma [LNCaP] (light tan); normal human embryonic stem cells [H1-hESC] (dark 
red); normal human umbilical vein endothelial cells [HUVEC] (brown); B-lymphocyte 
lymphoblastoid [GM12878] (blue); fetal lung fibroblasts [IMR90] (orange); cervical 
carcinoma [HeLa-S3] (purple). Arrows indicate the position of FAM13A. 
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3.1.6. Summary 
Using data available online, we were able to identify an intronic region in FAM13A that 
exhibits overlap between COPD and lung function associated GWAS SNPs and 
characteristics of a regulatory element including paired LD, H3K27ac marks, DNase I 
hypersensitivity, DNA conservation and TF binding. Furthermore, this intronic region 
was found to interact with the 5’ end of FAM13A, where the promoter is located, through 
chromatin looping. This indicates the presence of a putative active enhancer in lung 
function-associated intronic LD Block 3 within FAM13A that binds STAT-1.  
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3.2. In vitro identification of putative FAM13A enhancer 
3.2.1. FAM13A gene expression is increased in response to IFN-γ in normal 
bronchial epithelial cells but not in lung adenocarcinoma cells 
Given that IFN-γ is elevated in COPD lungs, and that the in-silico analysis predicts 
binding of STAT-1 to a putative enhancer in FAM13A, we first tested the responsiveness 
of FAM13A to IFN-γ. Both BEAS-2B and A549 cell lines were cultured in DMEM 
supplemented with 10% serum and treated with IFN-γ [10 ng/mL] for 0.5, 2, 6, and 24 
hours. 
In BEAS-2B cells, this resulted in a significant 6.1-fold increase in FAM13A (primer pair 
1) gene expression at 0.5-hour treatment which then decreases at 2-hours treatment to 
1.5-fold change, before increasing again at 6-hours treatment to reach 2.3-fold change 
and finally decreasing at 24-hours treatment to reach a minimum of 0.5-fold change 
(Figure 3.12A). Similarly, gene expression of FAM13A (primer pair 2) shows a 
significant increase at 0.5-hour treatment to reach a maximum of 2.5-fold increase, 
followed by a decrease to reach a minimum of 0.8-fold change at 6-hours before a slight 
increase to 0.9-fold change at 24-hours (Figure 3.12B). 
 In contrast, FAM13A (primer pair 1) gene expression in A549 cells showed a decrease to 
0.4-fold change that gradually increased to a maximum of 0.7-fold change at 6-hours 
treatment before decreasing again at 24-hours treatment to reach a minimum of 0.3-fold 
change (Figure 3.13A). Similarly, gene expression of FAM13A (primer pair 2) shows a 
gradual decrease to reach a minimum of 0.5-fold change at 6-hours treatment, followed 
by a slight increase to reach a maximum of 0.7-fold change at 24-hours (Figure 3.13B). 
Additionally, due to the role of IFN-γ in the dysregulation of EMT, we also studied the 
variation of gene expression of the epithelial marker CDH-1 and the mesenchymal marker 
CDH-2 which code for E-cadherin and N-cadherin respectively. The epithelial marker 
CDH-1 gene expression in BEAS-2B cells showed a 4-fold increase in expression at 0.5-
hour treatment followed by a gradual decrease to reach a minimum of 2.1-fold change at 
6-hours treatment and remained constant at 24-hours treatment (Figure 3.12C). In 
contrast, CDH-1 gene expression in A549 cells showed a gradual decrease over the 
chosen time points to reach a minimum of 0.4-fold change at 6-hours treatment followed 
by a slight increase at 24-hours treatment to reach a maximum of 0.7-fold change (Figure 
3.13C). The mesenchymal marker CDH-2 gene expression in BEAS-2B cells showed an 
62 
 
increase at 0.5-hour treatment to reach a maximum of 1.7-fold increase. This remained 
relatively constant before decreasing at 24-hour treatment to reach a minimum of 0.7-fold 
change (Figure 3.12D). On the other hand, CDH-2 gene expression in A549 cells showed 
greater variation in response to IFN-γ such that there was a decrease in gene expression 
at 0.5-hour treatment to reach a minimum of 0.6-fold change followed by gradual increase 
to reach a maximum of 1.7-fold increase at 6 hours. This dropped again at 24-hours to 
reach 0.7-fold change (Figure 3.13D). 
This indicates that FAM13A gene expression in response to IFN-γ treatment is opposite 
between normal and cancer cell lines such that it increases in the BEAS-2B cell line but 
decreases in the A549 cell line. This is accompanied by similar trends in the epithelial 
and mesenchymal markers CDH-1 and CDH-2 respectively, indicating possible EMT in 
response to IFN-γ in both cell lines. 
 
Figure 3.12: Gene expression fold change relative to no IFN-γ treatment in BEAS-2B cell line 
following time dependent IFN-γ treatment [10 ng/mL] administered at increasing time points 
(from 0 to 24 hours). Quantitative real-time PCR was used to analyse the expression of (A) 
FAM13A (primer pair 1), (B) FAM13A (primer pair 2), (C) CDH-1, and (D) CDH-2. Results 
represent 3 independent experiments. Note that n=3, mean =/- SD. 
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Figure 3.13: Gene expression fold change relative to no IFN-γ treatment in A549 cell line 
following time dependent IFN-γ treatment [10 ng/mL] administered at increasing time points 
(from 0 to 24 hours). Quantitative real-time PCR was used to analyse the expression of (A) 
FAM13A (primer pair 1), (B) FAM13A (primer pair 2), (C) CDH-1, and (D) CDH-2. Results 
represent 3 independent experiments. Note that n=3, mean =/- SD.  
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3.2.2. Putative FAM13A enhancer responds to IFN-γ treatment 
Having identified a possible lung function-associated enhancer in FAM13A and shown 
that FAM13A gene expression is regulated by IFN-γ, we wished to determine whether 
this putative enhancer also responds to IFN-γ treatment. To achieve this, both BEAS-2B 
and A549 cell lines were cultured DMEM supplemented with 5% serum and transfected 
with the pGL3-FAM13Aenh reporter construct cloned from normal epithelial cells and 
treated with IFN-γ [10 ng/mL] for 0.5, 2, 6 or 24 hours. 
Analysis of the lysates revealed that the inclusion of the enhancer did not increase 
luciferase activity above that seen from the control plasmid (Figure 3.14). In both BEAS-
2B and A549 cell lines, relative luciferase activity decreases slightly at 0.5-hour treatment 
to reach 0.61 and 0.53 relative activity compared to untreated control respectively before 
increasing in both cell lines at 2-hour treatment to reach 0.75 and 0.68 relative activity 
compared to untreated control respectively. However, at 6-hours treatment BEAS-2B 
cells show a decrease in luciferase activity while A549 cells show an increase in luciferase 
activity reaching 0.47 and 0.75 relative activity compared to untreated control 
respectively. This is then reversed at 24-hours treatment, such that BEAS-2B cells show 
an increase in relative luciferase activity and A549 cells show a decrease in relative 
luciferase activity compared to untreated control reaching 0.8 and 0.3 respectively. 
This indicates that the putative enhancer may in fact have a possible inhibitory effect on 
gene transcription in response to IFN-γ treatment in the BEAS-2B and the A549 cell lines 
at 6-hours and 24-hours respectively. 
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Figure 3.14: Relative luciferase activity relative to IFN-γ treatment in A549 and BEAS-2B cell 
lines. Results represent 3 independent experiments. Shown is the mean relative luciferase 
activity and standard deviation. Cells were transfected with pGL3-FAM13Aenh reporter 
construct and cultured in DMEM supplemented with 5% serum followed by time dependent 
IFN-γ treatment [10 ng/mL] administered at increasing time points (from 0 to 24 hours). 
Luciferase activity was normalized to the empty pGL3 vector.  
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3.2.3. Putative FAM13A enhancer is bound by IFN-γ-stimulated TFs 
Because the in-silico analysis of the identified putative enhancer in FAM13A was found 
to bind STAT-1 and because 3DSNP identified FAM13A itself as the interacting gene 
with the putative enhancer region, we wished to determine if the putative FAM13A 
enhancer is bound by the IFN-γ-stimulated transcription factor STAT-1 and whether its 
binding is influenced by IFN-γ treatment through ChIP (Figure 3.15). 
Both A549 and BEAS-2B cell lines were enriched with STAT-1 at 0-hour IFN-γ 
treatment. However, the BEAS-2B cell line had a significantly higher input percentage 
(100%) than the A549 cell line (15%). At 0.5-hour IFN-γ treatment, the input percentage 
decreased dramatically in the BEAS-2B cell line to reach 17% and continued to decrease 
to reach a minimum of 6% at 2-hour treatment. This then increases again at 6-hour 
treatment to reach 55% before decreasing again to 24% at 24-hours. As for the A549 cell 
line, the input percentage of STAT-1 increases at 0.5-hour IFN-γ treatment to reach a 
maximum average input percentage of 28% before gradually decreasing to reach a 
minimum of 9.5% at 24-hours treatment. 
Phosphorylated STAT-1 at 0-hour IFN-γ treatment was slightly higher in the A549 than 
the BEAS-2B cell line, such that the input percentage was 21% and 12.5% respectively. 
In the BEAS-2B cell line, the input percentage of phosphorylated STAT-1 gradually 
increases with IFN-γ treatment to reach a maximum of 37% at 6-hour treatment before 
decreasing at 24-hours treatment to reach a minimum of 21%. As for the A549 cell line, 
input percentage of phosphorylated STAT-1 showed greater variation with IFN-γ 
treatment such that at 0.5-hour treatment the input percentage decreased from 21% to 
10% before increasing again at 2-hour treatment to reach 20.5%. This then decreased at 
6-hour treatment to reach 17.5% before finally increasing at 24-hour IFN-γ treatment to 
reach a maximum average of input percentage of 26%. 
H3K4me3 input percentage at 0-hour IFN-γ treatment was 10.5% and 50.5% for the A549 
and the BEAS-2B cell lines respectively. Following treatment, the input percentage 
gradually decreased in the BEAS-2B cell line to reach a minimum of 16% at 6-hour IFN-
γ treatment before increasing again at 24-hours IFN-γ treatment to reach 27% input. As 
for the A549 and similar to the input percentage of phosphorylated STAT-1, the input 
percentage of H3K4me3 showed great variation following IFN-γ treatment such that at 
0.5-hour treatment it increased to reach 14% before decreasing at 2-hours treatment to 
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reach 10.5%. This then increases again at 6-hours IFN-γ treatment to reach a maximum 
of 23% before finally decreasing at 24-hours IFN-γ treatment to reach a minimum of 
7.5%. 
 
Figure 3.15: Percentage of input total STAT-1, phosphorylated STAT-1, and H3K4me3 at the 
identified FAM13A putative enhancer relative to time dependent IFN-γ treatment [10 ng/mL] 
administered at increasing time points (from 0 to 24 hours) in the (A) A549 and (B) BEAS-
2B cell lines. Results represent 2 individual experiments.  
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3.2.4. Differential regulation of FAM13A in response to IFN-γ between normal 
and cancer cells at the translational level 
3.2.4.1. Western Blot 
To examine whether the regulation of FAM13A at the transcriptional level in response to 
IFN-γ treatment is reflected at the translational level, both A549 and BEAS-2B whole 
cell lysates were analysed by Western Blot for FAM13A, TGF-β2 and β-catenin 
following time dependent IFN-γ treatment [10 ng/mL] administered at increasing time 
points (from 0 to 24 hours) (Figure 3.16). 
BEAS-2B cells did not express FAM13A prior to IFN-γ treatment. However, protein 
levels of FAM13A increased gradually with IFN-γ treatment between 0.5 and 24-hour 
treatment. Surprisingly, A549 cells showed a constant level of FAM13A prior to and 
following IFN-γ treatment. 
Furthermore, A549 cells only expressed TGF-β2 whose levels increased to reach a 
maximum between 0.5 and 2-hour treatments before decreasing again to minimal levels 
at 6-hours treatment and remaining constant up to 24-hours treatment. 
Moreover, β-catenin was expressed in both cell lines prior to IFN-γ treatment, however, 
A549 cells had a higher basal expression level. Following IFN-γ treatment, β-catenin 
levels remained relatively constant in the BEAS-2B cell line, whereas β-catenin levels in 
the A549 cell line showed a slight increase with IFN-γ treatment with a more distinct 
increase in expression levels at 24-hour treatment. 
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Figure 3.16: Western blot analysis whole cell lysate following time dependent IFN-γ 
treatment [10 ng/mL] administered at increasing time points (from 0 to 24 hours) in A549 
and BEAS-2B cell lines. * indicates high molecular weight isoform. 
3.2.4.2. Immunofluorescence 
To examine whether the distribution of phosphorylated STAT-1 might reflect the effect 
of IFN-γ on FAM13A, both A549 and BEAS-2B cell lines were immunohistochemically 
analysed following time dependent IFN-γ treatment [10 ng/mL] administered at 
increasing time points (from 0 to 6 hours) (Figure 3.17). 
Prior to IFN-γ treatment, only 0.4% of the BEAS-2B cells expressed phosphorylated 
STAT-1 compared to 2.8% of A549 cells. Following treatment, the percentage of cells 
expressing phosphorylated STAT-1 in BEAS-2B cells decreased slightly at 0.5-hour 
treatment to reach 0.24% before increasing gradually to reach a maximum of 1.22% at 6-
hour treatment. As for the A549 cells, the percentage of cells increased gradually with 
IFN-γ treatment to reach a maximum of 7.3% at 6-hour treatment. Although relatively 
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similar trends were seen in both cell lines, A549 cells showed greater responsiveness to 
IFN-γ treatment. 
 
Figure 3.17: Quantification of phospho-STAT-1 in A549 and BEAS-2B cell lines. (A) 
Representative image of A549 and BEAS-2B immunohistochemistry following time 
dependent IFN-γ treatment [10 ng/mL] administered at increasing time points (from 0 to 6 
hours). -Red: STAT-1(phosphorylated); Blue: Hoechst (nuclei). Scale bar 50µM. (B) 
Percentage of cells expressing phospho-STAT-1 in A549 and BEAS-2B cell lines. 
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4. Discussion and conclusion 
4.1. Discussion 
FAM13A has been repeatedly identified as a COPD and lung-function susceptibility gene 
through multiple GWAS (Cho et al., 2010; Cho et al., 2014; Hancock et al., 2012; Hobbs 
et al., 2017; Kim et al., 2015; Lutz et al., 2015; Pillai et al., 2009; Wain et al., 2017). 
Although it has recently been found to play a role in fatty acid oxidation and ROS 
production in response to cigarette smoke (Jiang et al., 2017), it is still unknown whether 
SNPs in FAM13A plays a more direct role in the development of COPD. 
4.1.1. Identification of putative regulatory elements 
Using publicly available data bases such as the NHGRI GWAS catalogue (Hindorff et 
al., 2009) and the UCSC genome browser (Kent et al., 2002), a locus of high linkage 
disequilibrium containing lung function-associated SNPs was identified that harbours 
epigenetic signatures indicative of the presence of a cis-regulatory element in lung 
epithelial cells within coordinates 89,884,589 and 89,886,005 on chromosome 4. These 
epigenetic signatures include the co-localization of histone H3 lysine 27 acetylation 
(H3K27ac), DNase I hypersensitivity, DNA conservation, and predicted binding of 
STAT-1. 
The in-silico analysis of the putative enhancer region revealed that although the human 
adenocarcinoma lung epithelial cell line, A549, had comparable H3K27ac signals to the 
human normal lung fibroblast cell line (NHLF) the DNase I hypersensitivity signals in 
the lung adenocarcinoma cell line (A549) were much lower than both the human normal 
lung fibroblast cell line (NHLF) and the normal small airway epithelial cell line (SAEC). 
DNA hypersensitivity to DNase I treatment is a result of depletion of nucleosomes and is 
therefore a reflection of chromatin remodelling at regions of enhancers (Heintzman et al., 
2007; Shlyueva et al., 2014). Consequently, loss of DNase I hypersensitivity signals in 
the A549 cell line indicates loss of open chromatin conformation required by transcription 
factors to bind. However, the functional analysis of the identified putative enhancer 
region in normal and cancer cell lines revealed a possible inhibitory effect in both the 
BEAS-2B and the A549 cell lines at 6-hours and 24-hours IFN-γ treatment respectively. 
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These results demonstrate one of the greatest challenges faced in establishing enhancer 
activity and in mapping enhancer interactions. Thousands of candidate distal enhancer 
regions across multiple human cell types have been predicted in recent studies by using 
genome-wide chromatin maps (Barski et al., 2007; Ernst and Kellis, 2010; Ernst et al., 
2011; Heintzman and Ren, 2009; Hesselberth et al., 2009). However, experimental 
validation of these enhancer regions has been achieved for only a small fraction of studies 
(Ernst et al., 2011). To address this challenge, recently developed strategies, such as 
massively parallel reporter assays (Arnold et al., 2013; Melnikov et al., 2012; Patwardhan 
et al., 2012; Sharon et al., 2012), take advantage of large-scale sequencing to 
simultaneously measure the activity of thousands of enhancer variants by systematic 
large-scale manipulations. Future experimental development and advances of these 
methods will allow an exhaustive testing of enhancer elements (Kheradpour et al., 2013) 
and therefore present more efficient and informative techniques. 
4.1.2. Regulation of FAM13A in normal and cancer cells 
Using 3DSNP (Lu et al., 2017), analysis of the COPD and lung-function associated SNPs 
located within the putative regulatory element revealed that this region loops to physically 
interact with FAM13A itself, therefore, FAM13A in both the normal and cancerous lung 
epithelial cell lines was analysed at the mRNA and protein level. 
Real-time qPCR analysis revealed that FAM13A is responsive to IFN-γ treatment in 
normal BEAS-2B cells, showing a significant increase at 0.5-hours treatment compared 
to no treatment. This increase was reflected at the protein level, such that FAM13A was 
not present before IFN-γ treatment in the BEAS-2B cell line but increased gradually 
following treatment. This regulation however, was lost in the adenocarcinoma A549 cell 
line. At the mRNA level, FAM13A levels in A549 cells remained relatively constant with 
time treatment. This was also reflected at the protein level such that A549 cells expressed 
FAM13A at constant levels even prior to IFN-γ treatment. 
This loss of regulation of FAM13A in cancer cells may have several implications relating 
to lung disease development and progression. FAM13A has been shown to decrease the 
stability of β-catenin in both human and murine COPD models (Jiang et al., 2016) such 
that the Wnt/β-catenin pathway is down-regulated in the epithelium of human COPD 
lungs (Wang et al., 2011). Furthermore, reduced expression of β-catenin has been 
associated with poor prognosis in adenocarcinoma (Kase et al., 2000; Retera et al., 1998). 
73 
 
Considering the major role of β-catenin in the Wnt/ β-catenin signalling pathway (Zou et 
al., 2013) in addition to the fact that the dysregulation of this pathway is a common 
occurrence in human cancers (Rapp et al., 2017; Zhan et al., 2017) implicates FAM13A 
as a possible candidate that contributes to the dysregulation of β-catenin in the context of 
COPD and lung cancer. 
Additionally, the EMT markers E-cadherin and N-cadherin also displayed gene 
expression changes that indicate a potential EMT-inducing effect of IFN-γ. The decrease 
in the epithelial marker CDH-1 gene expression and increase in the mesenchymal marker 
CDH-2 was observed in both cell lines. This ability of IFN-γ to induce an increase in 
FAM13A expression and in parallel induce EMT in a time dependent manner may be 
correlated and particularly important in the context of COPD. FAM13A has been recently 
shown to promote the degradation of β-catenin (Jiang et al., 2016), the major component 
of the adherens junctions and a key player in the Wnt/β-catenin signalling pathway. The 
subsequent loss of cell-cell adhesion may be one mechanism that contributes to EMT. 
The fact that EMT-like gene expression was observed in both A549 and BEAS-2B cell 
lines with an increase in FAM13A gene expression observed only in the BEAS-2B cell 
line indicates that the proposed relation between EMT, IFN-γ and FAM13A is not 
exclusive. 
Furthermore, analysis of the immunohistochemistry of both BEAS-2B and A549 cell 
lines following time dependent IFN-γ treatment revealed that the expression of 
phosphorylated STAT-1 is increased in response to IFN-γ treatment in both cell lines, 
however, A549 cells had 7-fold higher basal level of cells expressing STAT-1 than 
BEAS-2B cells. This fold difference was maintained throughout all time points studied 
indicating higher responsiveness of A549 cells to IFN-γ. Moreover, the low number of 
STAT-1 positive cells in both cell lines compared to the total number of cells reflects that 
a large portion of cells are unresponsive to IFN-γ treatment. This indicates that although 
cell lines used in research are considered to be homogenous populations, there exists 
subsets within these cells that behave or respond differently to the same treatment. 
Additionally, this provides a possible explanation of the small magnitude of change 
observed in the in vitro analysis of the pGL3-FAM13Aenh reporter construct such that if 
only about 8-10% of cells are responsive to the chosen treatment, the effect of IFN-γ on 
enhancer activity in these cells will be masked by the majority of unresponsive cells in 
the population. 
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4.1.3. Putative enhancer region and STAT-1 
The in-silico analysis of the putative enhancer region identified a conserved STAT-1 
binding motif. Binding of STAT-1 to the putative enhancer region was verified in vitro 
through ChIP in both A549 and BEAS-2B cell lines. The BEAS-2B cell line showed 100 
% enrichment prior to any treatment. This then decreased with IFN-γ treatment to reach 
a minimum at 2-hour treatment before increasing again but remaining below basal levels. 
As for the A549 cell line, it showed relatively constant enrichment for STAT-1 with IFN-
γ treatment. This indicates that in untreated normal cells, STAT-1 binds the putative 
enhancer region and could play a role in suppressing or decreasing FAM13A gene 
expression which is also reflected in the lack of FAM13A protein prior to IFN-γ 
treatment. IFN-γ treatment, and the consequent decrease in STAT-1 enrichment to the 
putative enhancer region is accompanied by a significant increase in FAM13A at both the 
mRNA and protein level. Additionally, the loss of regulation of STAT-1 binding to the 
putative enhancer region in the A549 cell line is also reflected at mRNA and protein level 
such that FAM13A levels remain relatively constant in response to IFN-γ treatment. This 
is not surprising as tumour cells often exhibit a dysregulated expression profile of STAT-
1 (Calo et al., 2003; Schindler, 2002) where responses to IFN may be the opposite of the 
normal responses (Qing and Stark, 2004). 
Genome-wide analyses in T cells showed that STATs are not only regulated by the 
epigenetic landscape of their target genes but also contribute to its remodelling (Kanno et 
al., 2012; O'Shea et al., 2011; Wilson et al., 2009). STATs have been described as core 
elements within multimolecular complexes that form at transcriptionally relevant DNA 
elements such as enhancers (Chen et al., 2008; Ciofani et al., 2012; Villarino et al., 2015). 
At enhancers, TFs act in an integrated combinatorial manner with varying outcomes such 
that both direct and indirect modes of transcription factor interaction and cooperation 
exist (Spitz and Furlong, 2012). In the additive model, for example, the concentration of 
individual TFs is proportional to enhancer activation (Spitz and Furlong, 2012). On the 
other hand, in the cooperative binding model, there exists a non-linear relationship 
between transcription factor concentration and the degree of occupancy of an enhancer 
region (Spitz and Furlong, 2012). This binding, which can result in switch-like effects, is 
associated with protein-protein interaction between TFs occupying adjacent sites in an 
enhancer region and therefore reinforcing each other’s DNA binding (Spitz and Furlong, 
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2012). Alternatively, TFs may cooperate without co-binding (Spitz and Furlong, 2012). 
For example, increased occupancy of individual TFs (Voss et al., 2011) may be the result 
of the co-expression of two TFs that compete for the same binding site (Spitz and Furlong, 
2012). Such net increase in TF binding is thought to be the result of counteracting 
nucleosome repositioning through rapidly alternating occupancy of either TF (Spitz and 
Furlong, 2012). Additionally, triggering local bending of DNA through TF binding may 
assist the binding of an adjacent TF to the enhancer (Falvo et al., 1995; Panne et al., 2007; 
Spitz and Furlong, 2012). Consequently, the enrichment of STAT-1 at the putative 
regulatory region prior to IFN-γ treatment with its decrease accompanied by an increase 
in transcription in normal cells may be due to either its recruitment of or displacement by 
other DNA-interacting proteins. 
4.1.4. COPD and lung cancer 
ChIP analysis of H3K4me3 enrichment revealed higher enrichment in BEAS-2B cells 
when compared to A549 cells such that H3K4me3 enrichment has been recently 
associated with increased transcription elongation and enhancer activity at tumour-
suppressor genes (Chen et al., 2015). This suggests a possible role for FAM13A as a 
tumour suppressor in lung epithelial cells in the context of inflammation. 
Several studies have demonstrated an increased incidence of lung cancer in COPD 
patients (Lange et al., 1990; Mannino et al., 2003; Sin et al., 2006; Skillrud, 1986; 
Tockman et al., 1987; Young et al., 2009) such that the repeated lung injury, aggressive 
inflammatory response and the compromised integrity of the epithelial barrier that 
characterize COPD lungs are sufficient to increase the risk for lung cancer development 
(Coussens and Werb, 2002; Houghton, 2013). Furthermore, the inhibition of the 
inflammatory response in COPD patients through treatment with inhaled corticosteroids 
results in the decrease of lung cancer incidence (Parimon et al., 2007). 
Genetic susceptibility plays a major role in the development of both COPD and lung 
cancer such that several SNPs in candidate gene families have been identified for both 
diseases. In fact, a FAM13A COPD-susceptibility SNP located within the identified LD 
Block 3 was found to confer a protective effect on COPD and non-small cell lung cancer 
independent of age, sex, height, lung function and smoking history (Young et al., 2011). 
Moreover, FAM13A has been recently identified as a novel hypoxia-induced gene in non-
small cell lung cancer (Ziolkowska-Suchanek et al., 2017). Another study has identified 
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FAM13A as a key regulator of non-small cell lung cancer growth and progression and 
demonstrated that FAM13A RhoGAP is associated with TH1 gene expression (Eisenhut 
et al., 2017). 
However, whether COPD and lung cancer are different manifestation of the same 
underlying molecular mechanisms and in response to genetic susceptibility 
environmental triggers remains to be verified.  
77 
 
4.2. Conclusion 
COPD is currently the fourth leading cause of mortality world-wide and its prevalence is 
expected to increase in the coming years. Moreover, COPD and lung cancer have been 
linked through the underlying processes that lead to their development and progression. 
Overall, this project reveals a possible link between COPD and lung cancer at the 
molecular level through an in vitro analysis of FAM13A, a COPD-susceptibility gene. We 
show for the first time that FAM13A is differentially regulated between normal lung 
epithelial cells and lung adenocarcinoma cells in response to IFN-γ, a key cytokine in the 
development of both COPD and lung cancer. Furthermore, the in-silico analysis of 
FAM13A identifies a putative regulatory element that may play a role in the dysregulation 
of FAM13A in lung adenocarcinoma cells in response to IFN-γ. Elucidating the molecular 
mechanisms of the regulation of FAM13A in the context of COPD and lung cancer allows 
the identification of potential diagnostic and therapeutic targets. Further research is 
needed to determine other regulatory elements and/or regulatory proteins that influence 
the differential regulation of FAM13A. 
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